Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Phase 2

Active, not recruiting

Conditions: Advanced Malignant Solid Neoplasm
Breast Carcinoma
Cervical Carcinoma
Liver Carcinoma
Malignant Uterine Neoplasm
Recurrent Gastric Carcinoma
Recurrent Head and Neck Carcinoma
Recurrent Ovarian Carcinoma
Recurrent Prostate Carcinoma
Recurrent Rectal Carcinoma

Interventions: Drug: Afatinib
Drug: Binimetinib
Drug: Adavosertib
Drug: Capivasertib
Drug: Afatinib Dimaleate
Procedure: Biospecimen Collection
Other: Cytology Specimen Collection Procedure
Drug: Dabrafenib
Drug: Fexagratinib
Drug: Dasatinib
Drug: Ipatasertib
Drug: Defactinib
Drug: Sapanisertib
Procedure: Biopsy
Drug: Crizotinib
Drug: Dabrafenib Mesylate
Drug: PI3K-beta Inhibitor GSK2636771
Drug: Defactinib Hydrochloride
Drug: Palbociclib
Biological: Nivolumab
Drug: Copanlisib
Drug: Taselisib
Drug: Ulixertinib
Drug: Copanlisib Hydrochloride
Biological: Trastuzumab Emtansine
Biological: Relatlimab
Procedure: Computed Tomography
Drug: Trametinib
Biological: Pertuzumab
Drug: Erdafitinib
Procedure: Radiologic Examination
Procedure: Multigated Acquisition Scan
Drug: Larotrectinib
Drug: Larotrectinib Sulfate
Procedure: Echocardiography
Drug: Osimertinib
Biological: Trastuzumab
Other: Laboratory Biomarker Analysis
Procedure: Magnetic Resonance Imaging
Drug: Vismodegib
Drug: Sunitinib Malate
Procedure: Radionuclide Imaging

Registration Number: NCT02465060

Lead Sponsor: National Cancer Institute (NCI)

Brief Summary: This phase II MATCH screening and multi-sub-trial studies how well treatment that is directed by genetic testing works in patients with solid tumors, lymphomas, or multiple myelomas that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) and does not respond to treatment (refractory). Patients must have progressed following at least one line of standard treatment or for which no agreed upon treatment approach exists. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with genetic abnormalities (such as mutations, amplifications, or translocations) may benefit more from treatment which targets their tumor's particular genetic abnormality. Identifying these genetic abnormalities first may help doctors plan better treatment for patients with solid tumors, lymphomas, or multiple myeloma.

Detailed Description: PRIMARY OBJECTIVE:

I. To evaluate the proportion of patients with objective response (OR) to targeted study agent(s) in patients with advanced refractory cancers/lymphomas/multiple myeloma.

SECONDARY OBJECTIVES:

I. To evaluate the proportion of patients alive and progression free at 6 months of treatment with targeted study agent in patients with advanced refractory cancers/lymphomas/multiple myeloma.

II. To evaluate time until death or disease progression. III. To identify potential predictive biomarkers beyond the genomic alteration by which treatment is assigned or resistance mechanisms using additional genomic, ribonucleic acid (RNA), protein and imaging-based assessment platforms.

IV. To assess whether radiomic phenotypes obtained from pre-treatment imaging and changes from pre- through post-therapy imaging can predict objective response and progression free survival and to evaluate the association between pre-treatment radiomic phenotypes and targeted gene mutation patterns of tumor biopsy specimens.

OUTLINE:

STEP 0 (Screening): Patients undergo biopsy along with molecular characterization of the biopsy material for specific, pre-defined mutations, amplifications, or translocations of interest via tumor sequencing and immunohistochemistry. Consenting patients also undergo collection of blood samples for research purposes.

STEPS 1, 3, 5, 7 (Treatment): Patients are assigned to 1 of 38 treatment subprotocols based on molecularly-defined subgroup. (See Arms Section)

STEPS 2, 4, 6 (Screening): Patients experiencing disease progression on the prior Step treatment or who could not tolerate the assigned treatment undergo review of their previous biopsy results to determine if another treatment is available or undergo another biopsy. Patients may have a maximum of 2 screening biopsies and 2 treatments per biopsy.

STEP 8 (Optional Research): Consenting patients undergo end-of-treatment biopsy and collection of blood samples for research purposes.

Additionally, patients may undergo a computed tomography (CT) scan, magnetic resonance imaging, and/or radionuclide imaging throughout the trial.

After completion of study treatment, patients are followed up every 3 months for 2 years and then every 6 months for 1 year.

Recruitment & Eligibility

Status: ACTIVE_NOT_RECRUITING

Sex: All

Target Recruitment: 6452

Inclusion Criteria

ELIGIBILITY CRITERIA FOR SCREENING BIOPSY (STEP 0)
Patients must be >= 18 years of age. Because no dosing or adverse event data are currently available on the use of study investigational agents in patients < 18 years of age, children are excluded from this study
Patients of childbearing potential must have a negative serum pregnancy test within 2 weeks prior to registration; patients that are pregnant or breast feeding are excluded; a patient of childbearing potential is anyone, regardless of sexual orientation or whether they have undergone tubal ligation, who meets the following criteria:
- Has achieved menarche at some point
- Has not undergone a hysterectomy or bilateral oophorectomy; or
- Has not been naturally postmenopausal for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months)
Patients must not expect to conceive or father children by using accepted and effective method(s) of contraception or by abstaining from sexual intercourse prior to study entry, for the duration of study participation, and for 4 months after completion of study; should a patient or partner of the patient become pregnant or suspect a pregnancy while participating in this study, the treating physician should be informed immediately
Patients must have histologically documented solid tumors or histologically confirmed diagnosis of lymphoma or multiple myeloma requiring therapy and meet one of the following criteria:
- Patients must have progressed following at least one line of standard systemic therapy and there must not be other approval/standard therapy available that has been shown to prolong overall survival (i.e. in a randomized trial against another standard treatment or by comparison to historical controls); patients who cannot receive other standard therapy that has been shown to prolong overall survival due to medical issues will be eligible, if other eligibility criteria are met; if the patient is currently receiving therapy, the clinician must have assessed that the current therapy is no longer benefitting the patient prior to enrolling on MATCH, regardless of whether it is considered standard OR
- Patients for whose disease no standard treatment exists that has been shown to prolong overall survival
- NOTE: No other prior malignancy is allowed except for the following:
- Adequately treated basal cell or squamous cell skin cancer
- In situ cervical cancer
- Adequately treated stage I or II cancer from which the patient is currently in complete remission
- Any other cancer from which the patient has been disease-free for 5 years
Patients must have measurable disease
Patients must meet the criteria below
- Tumor tissue for the confirmation of "rare variant" by the MATCH assay is to be submitted, preferably from the same time of collection as that used to determine patient candidacy for treatment arm assignment
  - Registration to Step 0 must occur after stopping prior systemic anti-cancer therapy. There is no specific duration for which patients must be off treatment prior to registration to Step 0, as long as all eligibility criteria are met
  - Patients may have received other non-targeted, immunotherapy or targeted treatment between the prior genetic testing at the outside lab and registration to Step 0. The decision to stop such treatment in favor of participation in MATCH, if no further clinical benefit is expected, is per the treating physician's discretion. Documentation of a lack of response to the prior treatment is not required in these cases
  - Patients with an applicable "rare variant" must be able to meet the eligibility criteria for the appropriate subprotocols within 4 weeks following notification of treatment assignment
  - Patient meets one of the following criteria:
    - Patient is a candidate for Z1M based on local Clinical Laboratory Improvement Act (CLIA) assessment of mismatch repair deficiency (MMRd) by immunohistochemistry (IHC) or microsatellite instability (MSI) status by polymerase chain reaction (PCR), adequate tumor tissue is available for submission for mandatory central screening IHC and the patient will be able to meet the eligibility criteria for Z1M within 4 weeks following notification of treatment assignment OR
    - The sites have received results from one of the designated outside laboratories indicating a "rare variant" that is an actionable Mutation of Interest (aMOI) for specific select subprotocols
- NOTE: There is no particular window of time after receiving the sequencing report notification of potential eligibility from an outside lab in which the patient must be registered to Step 0, but treatment slots will be assigned on a first come, first serve basis to those who do register to Step 0, and are not held for those notified of potential eligibility who do not register to Step 0
- NOTE: Treatment assignment (and the start of the associated deadline for Step 1 registration) may occur shortly after Step 0 registration. Note that certain "rare variant" arms require submission of archival tissue for central IHC testing to determine treatment assignment. For those arms, adequate tissue for the central IHC is required to be available for submission
- NOTE: Other potential aMOIs that would be eligibility criteria for "NON RARE" arms, as determined by the designated laboratories, are not applicable for this process in MATCH
Patient must not require the use of full dose coumarin-derivative anticoagulants such as warfarin; low molecular weight heparin is permitted for prophylactic or therapeutic use; factor X inhibitors are permitted
- NOTE: Warfarin may not be started while enrolled in the EAY131 study
- Stopping the anticoagulation for biopsy should be per site standard operating procedure (SOP)
Patients must have Eastern Cooperative Oncology Group (ECOG) performance status =< 1 and a life expectancy of at least 3 months
Patients must not currently be receiving any other investigational agents
Patients must not have any uncontrolled intercurrent illness including, but not limited to:
- Symptomatic congestive heart failure (New York Heart Association [NYHA] classification of III/IV)
- Unstable angina pectoris or coronary angioplasty, or stenting within 6 months prior to registration to Step 0, 2, 4, 6
- Cardiac arrhythmia (ongoing cardiac dysrhythmias of National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE] version [v]4 grade >= 2)
- Psychiatric illness/social situations that would limit compliance with study requirements
- Intra-cardiac defibrillators
- Known cardiac metastases
- Abnormal cardiac valve morphology (>= grade 2) documented by echocardiogram (ECHO) (as clinically indicated); (subjects with grade 1 abnormalities [i.e., mild regurgitation/stenosis] can be entered on study); subjects with moderate valvular thickening should not be entered on study
- NOTE: To receive an agent, patient must not have any uncontrolled intercurrent illness such as ongoing or active infection; patients with infections unlikely to be resolved within 2 weeks following screening should not be considered for the trial
Patients must be able to swallow tablets or capsules; a patient with any gastrointestinal disease that would impair ability to swallow, retain, or absorb drug is not eligible
Patients who are human immunodeficiency virus (HIV)-positive are eligible if:
- CD4+ cell count greater or equal to 250 cells/mm^3
- If patient is on antiretroviral therapy, there must be minimal interactions or overlapping toxicity of the antiretroviral therapy with the experimental cancer treatment; for experimental cancer therapeutics with CYP3A/4 interactions, protease inhibitor therapy is disallowed; suggested regimens to replace protease inhibitor therapy include dolutegravir given with tenofovir/emtricitabine; raltegravir given with tenofovir and emtricitabine; once daily combinations that use pharmacologic boosters may not be used
- No history of non-malignancy acquired immune deficiency syndrome (AIDS)-defining conditions other than historical low CD4+ cell counts
- Probable long-term survival with HIV if cancer were not present
Any prior therapy, radiotherapy (except palliative radiation therapy of 30 gray [Gy] or less), or major surgery must have been completed >= 4 weeks prior to start of treatment; all adverse events due to prior therapy have resolved to a grade 1 or better (except alopecia and lymphopenia) by start of treatment; palliative radiation therapy must have been completed at least 2 weeks prior to start of treatment; the radiotherapy must not be to a lesion that is included as measurable disease
- NOTE: Prostate cancer patients may continue their luteinizing hormone-releasing hormone (LHRH) agonist
- NOTE: For patients entering the study via the original screening process, patients may receive non-protocol treatment after biopsy (if clinically indicated) until they receive notification of results; however, lack of response must be documented prior to registration to Step 1; new non-protocol treatment will NOT be permitted as intervening therapy after registration to Step 0; the only intervening treatment permitted is prior therapy that the patient already received prior to Step 0 registration; the decision to stop the intervening non-protocol treatment will be left up to the treating physician if patient has an aMOI; however, patients will need to be off such therapy for at least 4 weeks before receiving any MATCH protocol treatment
- NOTE: For patients entering the study via a designated outside laboratory, no intervening systemic non-protocol treatment is permitted after Step 0 registration; all other eligibility requirements still apply to these patients, including the washouts for prior therapy noted above in this section, the time restrictions outlined, and the eligibility criteria for the intended subprotocol
Patients with brain metastases or primary brain tumors must have completed treatment, surgery or radiation therapy >= 4 weeks prior to start of treatment
Patients must have discontinued steroids >= 1 week prior to registration to Step 0 and remain off steroids thereafter, except as permitted; patients with glioblastoma (GBM) must have been on stable dose of steroids, or be off steroids, for one week prior to registration to treatment (Step 1, 3, 5, 7)
- NOTE: The following steroids are permitted (low dose steroid use is defined as prednisone 10 mg daily or less, or bioequivalent dose of other corticosteroid):
  - Temporary steroid use: e.g. for CT imaging in setting of contrast allergy
  - Low dose steroid use for appetite
  - Chronic inhaled steroid use
  - Steroid injections for joint disease
  - Stable dose of replacement steroid for adrenal insufficiency or low doses for non-malignant disease
  - Topical steroid
  - Steroids required to manage toxicity related to study treatment, as described in the subprotocols
  - Steroids required as pre- or post-chemotherapy medication for acceptable intervening chemotherapy
    - NOTE: Steroids must be completed alongside last dose of chemotherapy
Leukocytes >= 3,000/mcL (within 2 weeks prior to screening step registration and within 4 weeks prior to treatment step registration)
Absolute neutrophil count (ANC) >= 1,500/mcL (within 2 weeks prior to screening step registration and within 4 weeks prior to treatment step registration)
Platelets >= 100,000/mcL (within 2 weeks prior to screening step registration and within 4 weeks prior to treatment step registration)
NOTE: Patients with documented bone marrow involvement by lymphoma are not required to meet the above hematologic parameters, but must have a platelet count of at least 75,000/mcL and neutrophil count of at least 1,000/mcL
Total bilirubin =< 1.5 x institutional upper limit of normal (ULN) (unless documented Gilbert's syndrome, for which bilirubin =< 3 x institutional ULN is permitted) (within 2 weeks prior to screening step registration and within 4 weeks prior to treatment step registration)
Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2.5 x institutional ULN (up to 5 times ULN in presence of liver metastases) (within 2 weeks prior to screening step registration and within 4 weeks prior to treatment step registration)
Creatinine clearance >= 45 mL/min/1.73 m^2 for patients with creatinine levels above institutional ULN
- As defined by the Cockcroft-Gault equation (within 2 weeks prior to screening step registration and within 4 weeks prior to treatment step registration)
Patients must have an electrocardiogram (ECG) within 8 weeks prior to registration to screening step and must meet the following cardiac criteria:
- Resting corrected QT interval (QTc) =< 480 msec
  - NOTE: If the first recorded QTc exceeds 480 msec, two additional, consecutive ECGs are required and must result in a mean resting QTc =< 480 msec; it is recommended that there are 10-minute (+/- 5 minutes) breaks between the ECGs
- The following only need to be assessed if the mean QTc > 480 msec
  - Check potassium and magnesium serum levels
  - Correct any identified hypokalemia and/or hypomagnesemia and may repeat ECG to confirm exclusion of patient due to QTc
  - For patients with heart rate (HR) 60-100 beats per minute (bpm), no manual read of QTc is required
  - For patients with baseline HR < 60 or > 100 bpm, manual read of QT by trained personnel is required, with Fridericia correction applied to determine QTc
  - Patient must not have hypokalemia (value < institutional lower limit of normal)
- No factors that increase the risk of QTc prolongation or risk of arrhythmic events such as heart failure, congenital long QT syndrome, family history of long QT syndrome or unexplained sudden death under 40 years of age or any concomitant medication known to prolong the QT interval
  - NOTE: Patient must be taken off prohibited medication prior to registration to the screening step (Step 0, 2, 4, 6) and remain off these medications thereafter, unless permitted on a subprotocol for the management of treatment related toxicity; patient must be off the drug for at least 5 half-lives prior to registration to the treatment step (Step 1, 3, 5, 7); the medication half-life can be found in the package insert for Food and Drug Administration (FDA) approved drugs
ELIGIBILITY CRITERIA FOR FIRST TREATMENT (STEP 1)
NOTE: For patients entering step 0 with assay results from outside laboratories, no systemic treatment is allowed after step 0 registration
As MATCH is designed to add additional subprotocols, implement limited expansions of accrual for certain subprotocols, and/or amend existing arm-specific eligibility criteria, some patients entering under the original screening method may be eligible to have their results rerun in MATCHbox, even if they did not match to a treatment initially or did not receive a treatment assignment due to a lack of available assignment slots; patients whose sequence results will be rerun through MATCHbox must also meet the following criteria:
- Samples must have been collected within 5 months of the activation of the addendum, as there is an additional month needed to get the patients on trial
- Patient has not had treatment within the 5 months that resulted in a PR or better after the performance of the screening assessment
- Patient must meet eligibility criteria, including performance status 1 or better and life expectancy of at least 3 months
- Patients must meet the eligibility requirements with the following exceptions:
  - Patients may have received other non-targeted, immunotherapy or targeted treatment, which could be stopped in favor of returning to MATCH, if no response to the interim treatment has occurred and no further benefit is expected from this interim treatment, per the treating physician's discretion; documentation of a lack of response to the interim treatment is not required in these cases; however, the following restrictions apply:
    - Enrollment onto another investigational therapeutic study is not permitted
    - Patient cannot be responding to interim treatment, since the benefit of the MATCH treatment is unknown and may deprive patient of an effective treatment if it were given when a patient is responding to another treatment
- NOTE: Patients meeting these criteria will NOT be biopsied at this time point; instead, their step 0 results will be re-interrogated to determine if another treatment is available
ELIGIBILITY CRITERIA FOR SECOND SCREENING (STEP 2)
Patient's disease has progressed on Step 1 treatment or patient could not tolerate assigned treatment
- NOTE: PATIENTS ENTERING STEP 1 WITH A "RARE VARIANT" FROM AN "OUTSIDE" LAB ARE NOT ELIGIBLE FOR STEP 2
No response and progression (or inability to tolerate further treatment) occurred < 6 months from start of step 1 treatment
- NOTE: Patients meeting these criteria will NOT be biopsied at this time point; instead, their step 0 MATCH assay results will be re-interrogated to determine if another treatment is available upon registration to this study step; it is not necessary to confirm the availability of another potential treatment assignment in advance; only aMOIs detected by the MATCH assay may be used for the determination of eligibility to a relevant subprotocol OR
Progression (or inability to tolerate further treatment) occurred after a (1) response OR (2) after >= 6 months from start of step 1 treatment; patient must have tumor amenable to percutaneous biopsy and be willing and able to undergo a tumor biopsy or bone marrow aspirate for collection and submission of tumor tissue OR patient will be undergoing a procedure due to medical necessity during which the tissue may be collected for the central determination of the presence of one or more of the specific "actionable" mutations/amplifications of interest (aMOI); archived specimens cannot be accepted
Patients must meet eligibility criteria as defined in step 0
Patient must not have been assigned to step 1 treatment based on a "rare variant" determined by a designated outside laboratory
ELIGIBILITY CRITERIA FOR SECOND TREATMENT (STEP 3)
NOTE: If screening biopsy samples were submitted during step 2, patients may receive non-protocol treatment after biopsy (if clinically indicated) until they receive notification of results however, lack of response must be documented prior to registration to step 3; new non-protocol treatment will NOT be permitted as intervening therapy after registration to step 2; the decision to stop the intervening nonprotocol treatment will be left up to the treating physician if patient has an aMOI; waiting periods as described will apply
ELIGIBILITY CRITERIA FOR THIRD SCREENING (STEP 4)
Patient's disease has progressed on step 3 treatment or patient could not tolerate assigned treatment
- Patient must meet one of the following criteria:
  - No response and progression (or inability to tolerate further treatment) occurred < 6 months from start of step 3 (second) treatment AND a biopsy was performed at step 2 screening
    - NOTE: Patients meeting these criteria will NOT be biopsied at this time point; instead, their latest MATCH assay results will be re-interrogated to determine if another treatment is available upon registration to this study step; it is not necessary to confirm the availability of another potential treatment assignment in advance OR
  - Progression (or inability to tolerate further treatment) occurred on step 3 treatment and a biopsy was not performed at step 2 screening

Exclusion Criteria

Not provided

Study Type: INTERVENTIONAL

Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Subprotocol L (mTOR mutation)	Sapanisertib	Patients with mTOR mutation receive sapanisertib PO daily on days 1-28. Cycles repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
Subprotocol M (TSC1 or TSC2 mutation)	Sapanisertib	Patients with TSC1 or TSC2 mutation receive sapanisertib PO daily on days 1-28. Cycles repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
Subprotocol Z1F (PIK3CA mutation)	Copanlisib Hydrochloride	Patients receive copanlisib IV over 1 hour on days 1, 8, and 15 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo tumor biopsies at screening and end of treatment as well as CT or MRI at baseline and repeated every 2 cycles for the first 26 cycles then every 3 cycles thereafter until progressive disease or start of another MATCH treatment step.
Subprotocol Z1G (PTEN loss)	Copanlisib Hydrochloride	Patients with PTEN loss receive copanlisib IV over 1 hour on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Subprotocol Z1H (PTEN mutation)	Copanlisib Hydrochloride	Patients with PTEN mutation receive copanlisib IV over 1 hour on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Subprotocol B (HER2 activating mutation)	Afatinib Dimaleate	Patients with HER2 activating mutation receive afatinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Subprotocol A (EGFR activating mutation)	Afatinib Dimaleate	Patients with EGFR activating mutation receive afatinib orally (PO) once daily (QD) on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo CT or MRI during screening and on study, as well as during follow-up as clinically necessary. Patients may also undergo ECHO or nuclear study throughout the trial as clinically necessary. Patients undergo biopsies and blood sample collection on study.
Subprotocol Z1E (NTRK1, NTRK2 or NTRK3 gene fusion)	Larotrectinib Sulfate	Patients with NTRK1, NTRK2, or NTRK3 gene fusion receive larotrectinib (LOXO-101) PO BID on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo CT or MRI during screening and on study, as well as during follow-up as clinically necessary. Patients also undergo biopsies and blood sample collection on study.
Subprotocol C1 (MET amplification)	Biospecimen Collection	Patients with MET amplification receive crizotinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo radiologic evaluation and collection of blood samples throughout the study. Patients may undergo biopsy at screening, on study, and/or at end of treatment.
Subprotocol G (ROS1 translocation or inversion)	Cytology Specimen Collection Procedure	Patients with ROS1 translocation or inversion receive crizotinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Subprotocol A (EGFR activating mutation)	Afatinib	Patients with EGFR activating mutation receive afatinib orally (PO) once daily (QD) on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo CT or MRI during screening and on study, as well as during follow-up as clinically necessary. Patients may also undergo ECHO or nuclear study throughout the trial as clinically necessary. Patients undergo biopsies and blood sample collection on study.
Subprotocol A (EGFR activating mutation)	Biopsy	Patients with EGFR activating mutation receive afatinib orally (PO) once daily (QD) on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo CT or MRI during screening and on study, as well as during follow-up as clinically necessary. Patients may also undergo ECHO or nuclear study throughout the trial as clinically necessary. Patients undergo biopsies and blood sample collection on study.
Subprotocol A (EGFR activating mutation)	Biospecimen Collection	Patients with EGFR activating mutation receive afatinib orally (PO) once daily (QD) on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo CT or MRI during screening and on study, as well as during follow-up as clinically necessary. Patients may also undergo ECHO or nuclear study throughout the trial as clinically necessary. Patients undergo biopsies and blood sample collection on study.
Subprotocol A (EGFR activating mutation)	Computed Tomography	Patients with EGFR activating mutation receive afatinib orally (PO) once daily (QD) on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo CT or MRI during screening and on study, as well as during follow-up as clinically necessary. Patients may also undergo ECHO or nuclear study throughout the trial as clinically necessary. Patients undergo biopsies and blood sample collection on study.
Subprotocol A (EGFR activating mutation)	Cytology Specimen Collection Procedure	Patients with EGFR activating mutation receive afatinib orally (PO) once daily (QD) on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo CT or MRI during screening and on study, as well as during follow-up as clinically necessary. Patients may also undergo ECHO or nuclear study throughout the trial as clinically necessary. Patients undergo biopsies and blood sample collection on study.
Subprotocol A (EGFR activating mutation)	Echocardiography	Patients with EGFR activating mutation receive afatinib orally (PO) once daily (QD) on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo CT or MRI during screening and on study, as well as during follow-up as clinically necessary. Patients may also undergo ECHO or nuclear study throughout the trial as clinically necessary. Patients undergo biopsies and blood sample collection on study.
Subprotocol A (EGFR activating mutation)	Laboratory Biomarker Analysis	Patients with EGFR activating mutation receive afatinib orally (PO) once daily (QD) on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo CT or MRI during screening and on study, as well as during follow-up as clinically necessary. Patients may also undergo ECHO or nuclear study throughout the trial as clinically necessary. Patients undergo biopsies and blood sample collection on study.
Subprotocol A (EGFR activating mutation)	Magnetic Resonance Imaging	Patients with EGFR activating mutation receive afatinib orally (PO) once daily (QD) on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo CT or MRI during screening and on study, as well as during follow-up as clinically necessary. Patients may also undergo ECHO or nuclear study throughout the trial as clinically necessary. Patients undergo biopsies and blood sample collection on study.
Subprotocol A (EGFR activating mutation)	Radionuclide Imaging	Patients with EGFR activating mutation receive afatinib orally (PO) once daily (QD) on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo CT or MRI during screening and on study, as well as during follow-up as clinically necessary. Patients may also undergo ECHO or nuclear study throughout the trial as clinically necessary. Patients undergo biopsies and blood sample collection on study.
Subprotocol B (HER2 activating mutation)	Afatinib	Patients with HER2 activating mutation receive afatinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Subprotocol B (HER2 activating mutation)	Cytology Specimen Collection Procedure	Patients with HER2 activating mutation receive afatinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Subprotocol B (HER2 activating mutation)	Laboratory Biomarker Analysis	Patients with HER2 activating mutation receive afatinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Subprotocol C1 (MET amplification)	Biopsy	Patients with MET amplification receive crizotinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo radiologic evaluation and collection of blood samples throughout the study. Patients may undergo biopsy at screening, on study, and/or at end of treatment.
Subprotocol G (ROS1 translocation or inversion)	Laboratory Biomarker Analysis	Patients with ROS1 translocation or inversion receive crizotinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Subprotocol C1 (MET amplification)	Crizotinib	Patients with MET amplification receive crizotinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo radiologic evaluation and collection of blood samples throughout the study. Patients may undergo biopsy at screening, on study, and/or at end of treatment.
Subprotocol C1 (MET amplification)	Cytology Specimen Collection Procedure	Patients with MET amplification receive crizotinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo radiologic evaluation and collection of blood samples throughout the study. Patients may undergo biopsy at screening, on study, and/or at end of treatment.
Subprotocol C1 (MET amplification)	Laboratory Biomarker Analysis	Patients with MET amplification receive crizotinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo radiologic evaluation and collection of blood samples throughout the study. Patients may undergo biopsy at screening, on study, and/or at end of treatment.
Subprotocol C1 (MET amplification)	Radiologic Examination	Patients with MET amplification receive crizotinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo radiologic evaluation and collection of blood samples throughout the study. Patients may undergo biopsy at screening, on study, and/or at end of treatment.
Subprotocol C2 (MET exon 14 deletion/mutation)	Biopsy	Patients with MET exon 14 deletion or other mutations that disrupt exon 14 receive crizotinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo tumor biopsy on study and undergo radiologic evaluation and blood sample collection throughout the study.
Subprotocol C2 (MET exon 14 deletion/mutation)	Biospecimen Collection	Patients with MET exon 14 deletion or other mutations that disrupt exon 14 receive crizotinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo tumor biopsy on study and undergo radiologic evaluation and blood sample collection throughout the study.
Subprotocol C2 (MET exon 14 deletion/mutation)	Crizotinib	Patients with MET exon 14 deletion or other mutations that disrupt exon 14 receive crizotinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo tumor biopsy on study and undergo radiologic evaluation and blood sample collection throughout the study.
Subprotocol C2 (MET exon 14 deletion/mutation)	Cytology Specimen Collection Procedure	Patients with MET exon 14 deletion or other mutations that disrupt exon 14 receive crizotinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo tumor biopsy on study and undergo radiologic evaluation and blood sample collection throughout the study.
Subprotocol C2 (MET exon 14 deletion/mutation)	Laboratory Biomarker Analysis	Patients with MET exon 14 deletion or other mutations that disrupt exon 14 receive crizotinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo tumor biopsy on study and undergo radiologic evaluation and blood sample collection throughout the study.
Subprotocol C2 (MET exon 14 deletion/mutation)	Radiologic Examination	Patients with MET exon 14 deletion or other mutations that disrupt exon 14 receive crizotinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo tumor biopsy on study and undergo radiologic evaluation and blood sample collection throughout the study.
Subprotocol E (EGFR T790M or rare activating mutation)	Biopsy	Patients with EGFR T790M or rare activating mutation receive osimertinib (AZD9291) PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo radiologic evaluation throughout the trial, ECHO or multigated acquisition scan (MUGA) during screening, and biopsy and collection of blood samples on trial and at end of treatment.
Subprotocol E (EGFR T790M or rare activating mutation)	Biospecimen Collection	Patients with EGFR T790M or rare activating mutation receive osimertinib (AZD9291) PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo radiologic evaluation throughout the trial, ECHO or multigated acquisition scan (MUGA) during screening, and biopsy and collection of blood samples on trial and at end of treatment.
Subprotocol E (EGFR T790M or rare activating mutation)	Cytology Specimen Collection Procedure	Patients with EGFR T790M or rare activating mutation receive osimertinib (AZD9291) PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo radiologic evaluation throughout the trial, ECHO or multigated acquisition scan (MUGA) during screening, and biopsy and collection of blood samples on trial and at end of treatment.
Subprotocol E (EGFR T790M or rare activating mutation)	Echocardiography	Patients with EGFR T790M or rare activating mutation receive osimertinib (AZD9291) PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo radiologic evaluation throughout the trial, ECHO or multigated acquisition scan (MUGA) during screening, and biopsy and collection of blood samples on trial and at end of treatment.
Subprotocol E (EGFR T790M or rare activating mutation)	Laboratory Biomarker Analysis	Patients with EGFR T790M or rare activating mutation receive osimertinib (AZD9291) PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo radiologic evaluation throughout the trial, ECHO or multigated acquisition scan (MUGA) during screening, and biopsy and collection of blood samples on trial and at end of treatment.
Subprotocol E (EGFR T790M or rare activating mutation)	Multigated Acquisition Scan	Patients with EGFR T790M or rare activating mutation receive osimertinib (AZD9291) PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo radiologic evaluation throughout the trial, ECHO or multigated acquisition scan (MUGA) during screening, and biopsy and collection of blood samples on trial and at end of treatment.
Subprotocol E (EGFR T790M or rare activating mutation)	Osimertinib	Patients with EGFR T790M or rare activating mutation receive osimertinib (AZD9291) PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo radiologic evaluation throughout the trial, ECHO or multigated acquisition scan (MUGA) during screening, and biopsy and collection of blood samples on trial and at end of treatment.
Subprotocol E (EGFR T790M or rare activating mutation)	Radiologic Examination	Patients with EGFR T790M or rare activating mutation receive osimertinib (AZD9291) PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo radiologic evaluation throughout the trial, ECHO or multigated acquisition scan (MUGA) during screening, and biopsy and collection of blood samples on trial and at end of treatment.
Subprotocol F (ALK translocation)	Crizotinib	Patients with ALK translocation receive crizotinib PO twice daily (BID) on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Subprotocol F (ALK translocation)	Cytology Specimen Collection Procedure	Patients with ALK translocation receive crizotinib PO twice daily (BID) on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Subprotocol F (ALK translocation)	Laboratory Biomarker Analysis	Patients with ALK translocation receive crizotinib PO twice daily (BID) on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Subprotocol G (ROS1 translocation or inversion)	Crizotinib	Patients with ROS1 translocation or inversion receive crizotinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Subprotocol H (BRAF V600E/R/K/D mutation)	Cytology Specimen Collection Procedure	Patients with BRAF V600E/R/K/D mutation receive dabrafenib PO BID and trametinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Subprotocol H (BRAF V600E/R/K/D mutation)	Dabrafenib	Patients with BRAF V600E/R/K/D mutation receive dabrafenib PO BID and trametinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Subprotocol H (BRAF V600E/R/K/D mutation)	Dabrafenib Mesylate	Patients with BRAF V600E/R/K/D mutation receive dabrafenib PO BID and trametinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Subprotocol H (BRAF V600E/R/K/D mutation)	Laboratory Biomarker Analysis	Patients with BRAF V600E/R/K/D mutation receive dabrafenib PO BID and trametinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Subprotocol H (BRAF V600E/R/K/D mutation)	Trametinib	Patients with BRAF V600E/R/K/D mutation receive dabrafenib PO BID and trametinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Subprotocol I (PIK3CA mutation)	Cytology Specimen Collection Procedure	Patients with PIK3CA mutation without RAS mutation or PTEN loss receive taselisib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Subprotocol I (PIK3CA mutation)	Laboratory Biomarker Analysis	Patients with PIK3CA mutation without RAS mutation or PTEN loss receive taselisib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Subprotocol J (HER2 amplification >= 7 copy numbers)	Biopsy	Patients receive pertuzumab IV over 30-60 minutes and trastuzumab IV over 30 minutes on day 1 of each cycle. Cycles repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients also undergo radiologic evaluation throughout the trial, ECHO at screening and end of treatment, and biopsy and collection of blood samples on trial and at end of treatment.
Subprotocol J (HER2 amplification >= 7 copy numbers)	Biospecimen Collection	Patients receive pertuzumab IV over 30-60 minutes and trastuzumab IV over 30 minutes on day 1 of each cycle. Cycles repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients also undergo radiologic evaluation throughout the trial, ECHO at screening and end of treatment, and biopsy and collection of blood samples on trial and at end of treatment.
Subprotocol J (HER2 amplification >= 7 copy numbers)	Echocardiography	Patients receive pertuzumab IV over 30-60 minutes and trastuzumab IV over 30 minutes on day 1 of each cycle. Cycles repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients also undergo radiologic evaluation throughout the trial, ECHO at screening and end of treatment, and biopsy and collection of blood samples on trial and at end of treatment.
Subprotocol J (HER2 amplification >= 7 copy numbers)	Laboratory Biomarker Analysis	Patients receive pertuzumab IV over 30-60 minutes and trastuzumab IV over 30 minutes on day 1 of each cycle. Cycles repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients also undergo radiologic evaluation throughout the trial, ECHO at screening and end of treatment, and biopsy and collection of blood samples on trial and at end of treatment.
Subprotocol M (TSC1 or TSC2 mutation)	Laboratory Biomarker Analysis	Patients with TSC1 or TSC2 mutation receive sapanisertib PO daily on days 1-28. Cycles repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
Subprotocol J (HER2 amplification >= 7 copy numbers)	Pertuzumab	Patients receive pertuzumab IV over 30-60 minutes and trastuzumab IV over 30 minutes on day 1 of each cycle. Cycles repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients also undergo radiologic evaluation throughout the trial, ECHO at screening and end of treatment, and biopsy and collection of blood samples on trial and at end of treatment.
Subprotocol J (HER2 amplification >= 7 copy numbers)	Radiologic Examination	Patients receive pertuzumab IV over 30-60 minutes and trastuzumab IV over 30 minutes on day 1 of each cycle. Cycles repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients also undergo radiologic evaluation throughout the trial, ECHO at screening and end of treatment, and biopsy and collection of blood samples on trial and at end of treatment.
Subprotocol J (HER2 amplification >= 7 copy numbers)	Trastuzumab	Patients receive pertuzumab IV over 30-60 minutes and trastuzumab IV over 30 minutes on day 1 of each cycle. Cycles repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients also undergo radiologic evaluation throughout the trial, ECHO at screening and end of treatment, and biopsy and collection of blood samples on trial and at end of treatment.
Subprotocol K1 (FGFR amplification)	Biopsy	Patients with FGFR amplification receive erdafitinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT and MRI throughout study. Patients may also undergo blood sample collection and tumor biopsy throughout the trial.
Subprotocol K1 (FGFR amplification)	Biospecimen Collection	Patients with FGFR amplification receive erdafitinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT and MRI throughout study. Patients may also undergo blood sample collection and tumor biopsy throughout the trial.
Subprotocol K1 (FGFR amplification)	Computed Tomography	Patients with FGFR amplification receive erdafitinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT and MRI throughout study. Patients may also undergo blood sample collection and tumor biopsy throughout the trial.
Subprotocol K1 (FGFR amplification)	Cytology Specimen Collection Procedure	Patients with FGFR amplification receive erdafitinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT and MRI throughout study. Patients may also undergo blood sample collection and tumor biopsy throughout the trial.
Subprotocol K1 (FGFR amplification)	Erdafitinib	Patients with FGFR amplification receive erdafitinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT and MRI throughout study. Patients may also undergo blood sample collection and tumor biopsy throughout the trial.
Subprotocol K1 (FGFR amplification)	Laboratory Biomarker Analysis	Patients with FGFR amplification receive erdafitinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT and MRI throughout study. Patients may also undergo blood sample collection and tumor biopsy throughout the trial.
Subprotocol K1 (FGFR amplification)	Magnetic Resonance Imaging	Patients with FGFR amplification receive erdafitinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT and MRI throughout study. Patients may also undergo blood sample collection and tumor biopsy throughout the trial.
Subprotocol K2 (FGFR mutation or fusion)	Biopsy	Patients with FGFR mutation or fusion receive erdafitinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo blood sample collection, CT or MRI, and tumor biopsy throughout the study.
Subprotocol K2 (FGFR mutation or fusion)	Biospecimen Collection	Patients with FGFR mutation or fusion receive erdafitinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo blood sample collection, CT or MRI, and tumor biopsy throughout the study.
Subprotocol K2 (FGFR mutation or fusion)	Computed Tomography	Patients with FGFR mutation or fusion receive erdafitinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo blood sample collection, CT or MRI, and tumor biopsy throughout the study.
Subprotocol K2 (FGFR mutation or fusion)	Cytology Specimen Collection Procedure	Patients with FGFR mutation or fusion receive erdafitinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo blood sample collection, CT or MRI, and tumor biopsy throughout the study.
Subprotocol K2 (FGFR mutation or fusion)	Erdafitinib	Patients with FGFR mutation or fusion receive erdafitinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo blood sample collection, CT or MRI, and tumor biopsy throughout the study.
Subprotocol K2 (FGFR mutation or fusion)	Laboratory Biomarker Analysis	Patients with FGFR mutation or fusion receive erdafitinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo blood sample collection, CT or MRI, and tumor biopsy throughout the study.
Subprotocol K2 (FGFR mutation or fusion)	Magnetic Resonance Imaging	Patients with FGFR mutation or fusion receive erdafitinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo blood sample collection, CT or MRI, and tumor biopsy throughout the study.
Subprotocol L (mTOR mutation)	Cytology Specimen Collection Procedure	Patients with mTOR mutation receive sapanisertib PO daily on days 1-28. Cycles repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
Subprotocol L (mTOR mutation)	Laboratory Biomarker Analysis	Patients with mTOR mutation receive sapanisertib PO daily on days 1-28. Cycles repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
Subprotocol M (TSC1 or TSC2 mutation)	Cytology Specimen Collection Procedure	Patients with TSC1 or TSC2 mutation receive sapanisertib PO daily on days 1-28. Cycles repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
Subprotocol N (PTEN mutation or deletion and PTEN expression)	Cytology Specimen Collection Procedure	Patients with PTEN mutation or deletion and PTEN expression receive PI3K-beta inhibitor GSK2636771 PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Subprotocol N (PTEN mutation or deletion and PTEN expression)	Laboratory Biomarker Analysis	Patients with PTEN mutation or deletion and PTEN expression receive PI3K-beta inhibitor GSK2636771 PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Subprotocol N (PTEN mutation or deletion and PTEN expression)	PI3K-beta Inhibitor GSK2636771	Patients with PTEN mutation or deletion and PTEN expression receive PI3K-beta inhibitor GSK2636771 PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Subprotocol P (PTEN loss)	Cytology Specimen Collection Procedure	Patients with PTEN loss receive PI3K-beta inhibitor GSK2636771 PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Subprotocol P (PTEN loss)	Laboratory Biomarker Analysis	Patients with PTEN loss receive PI3K-beta inhibitor GSK2636771 PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Subprotocol P (PTEN loss)	PI3K-beta Inhibitor GSK2636771	Patients with PTEN loss receive PI3K-beta inhibitor GSK2636771 PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Subprotocol Q (HER2 amplification)	Cytology Specimen Collection Procedure	Patients with HER2 amplification receive trastuzumab emtansine intravenously (IV) over 30-90 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
Subprotocol Q (HER2 amplification)	Laboratory Biomarker Analysis	Patients with HER2 amplification receive trastuzumab emtansine intravenously (IV) over 30-90 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
Subprotocol Q (HER2 amplification)	Trastuzumab	Patients with HER2 amplification receive trastuzumab emtansine intravenously (IV) over 30-90 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
Subprotocol T (SMO or PTCH1 mutation)	Cytology Specimen Collection Procedure	Patients with SMO or PTCH1 mutation receive vismodegib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo ECHO or nuclear study during screening, tumor biopsy on study and CT scan, MRI and blood sample collection throughout the study.
Subprotocol Q (HER2 amplification)	Trastuzumab Emtansine	Patients with HER2 amplification receive trastuzumab emtansine intravenously (IV) over 30-90 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
Subprotocol R (BRAF fusion or BRAF non-V600 mutation)	Cytology Specimen Collection Procedure	Patients with BRAF fusion or BRAF non-V600 mutation receive trametinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Subprotocol R (BRAF fusion or BRAF non-V600 mutation)	Laboratory Biomarker Analysis	Patients with BRAF fusion or BRAF non-V600 mutation receive trametinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Subprotocol R (BRAF fusion or BRAF non-V600 mutation)	Trametinib	Patients with BRAF fusion or BRAF non-V600 mutation receive trametinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Subprotocol S1 (NF1 mutation)	Cytology Specimen Collection Procedure	Patients with NF1 mutation receive trametinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Subprotocol S1 (NF1 mutation)	Laboratory Biomarker Analysis	Patients with NF1 mutation receive trametinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Subprotocol S1 (NF1 mutation)	Trametinib	Patients with NF1 mutation receive trametinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Subprotocol S2 (GNAQ or GNA11 mutation)	Cytology Specimen Collection Procedure	Patients with GNAQ or GNA11 mutation receive trametinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Subprotocol S2 (GNAQ or GNA11 mutation)	Laboratory Biomarker Analysis	Patients with GNAQ or GNA11 mutation receive trametinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Subprotocol S2 (GNAQ or GNA11 mutation)	Trametinib	Patients with GNAQ or GNA11 mutation receive trametinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Subprotocol T (SMO or PTCH1 mutation)	Biopsy	Patients with SMO or PTCH1 mutation receive vismodegib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo ECHO or nuclear study during screening, tumor biopsy on study and CT scan, MRI and blood sample collection throughout the study.
Subprotocol T (SMO or PTCH1 mutation)	Biospecimen Collection	Patients with SMO or PTCH1 mutation receive vismodegib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo ECHO or nuclear study during screening, tumor biopsy on study and CT scan, MRI and blood sample collection throughout the study.
Subprotocol T (SMO or PTCH1 mutation)	Computed Tomography	Patients with SMO or PTCH1 mutation receive vismodegib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo ECHO or nuclear study during screening, tumor biopsy on study and CT scan, MRI and blood sample collection throughout the study.
Subprotocol T (SMO or PTCH1 mutation)	Echocardiography	Patients with SMO or PTCH1 mutation receive vismodegib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo ECHO or nuclear study during screening, tumor biopsy on study and CT scan, MRI and blood sample collection throughout the study.
Subprotocol T (SMO or PTCH1 mutation)	Laboratory Biomarker Analysis	Patients with SMO or PTCH1 mutation receive vismodegib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo ECHO or nuclear study during screening, tumor biopsy on study and CT scan, MRI and blood sample collection throughout the study.
Subprotocol T (SMO or PTCH1 mutation)	Magnetic Resonance Imaging	Patients with SMO or PTCH1 mutation receive vismodegib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo ECHO or nuclear study during screening, tumor biopsy on study and CT scan, MRI and blood sample collection throughout the study.
Subprotocol T (SMO or PTCH1 mutation)	Radionuclide Imaging	Patients with SMO or PTCH1 mutation receive vismodegib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo ECHO or nuclear study during screening, tumor biopsy on study and CT scan, MRI and blood sample collection throughout the study.
Subprotocol T (SMO or PTCH1 mutation)	Vismodegib	Patients with SMO or PTCH1 mutation receive vismodegib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo ECHO or nuclear study during screening, tumor biopsy on study and CT scan, MRI and blood sample collection throughout the study.
Subprotocol U (NF2 inactivating mutation)	Cytology Specimen Collection Procedure	Patients with NF2 inactivating mutation receive defactinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Subprotocol U (NF2 inactivating mutation)	Defactinib Hydrochloride	Patients with NF2 inactivating mutation receive defactinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Subprotocol U (NF2 inactivating mutation)	Laboratory Biomarker Analysis	Patients with NF2 inactivating mutation receive defactinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Subprotocol V (cKIT exon 9, 11, 13, or 14 mutation)	Biopsy	Patients with cKIT exon 9, 11, 13, or 14 mutation receive sunitinib PO QD on days 1-28 of each cycle. Cycles repeat every 42 days in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo CT or MRI during screening and on study, as well as during follow-up as clinically necessary. Patients also undergo ECHO or nuclear study throughout the trial as clinically necessary. Patients undergo biopsies and blood sample collection on study.
Subprotocol V (cKIT exon 9, 11, 13, or 14 mutation)	Biospecimen Collection	Patients with cKIT exon 9, 11, 13, or 14 mutation receive sunitinib PO QD on days 1-28 of each cycle. Cycles repeat every 42 days in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo CT or MRI during screening and on study, as well as during follow-up as clinically necessary. Patients also undergo ECHO or nuclear study throughout the trial as clinically necessary. Patients undergo biopsies and blood sample collection on study.
Subprotocol X (DDR2 S768R, I638F, or L239R mutation)	Cytology Specimen Collection Procedure	Patients with DDR2 S768R, I638F, or L239R mutation receive dasatinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Subprotocol V (cKIT exon 9, 11, 13, or 14 mutation)	Computed Tomography	Patients with cKIT exon 9, 11, 13, or 14 mutation receive sunitinib PO QD on days 1-28 of each cycle. Cycles repeat every 42 days in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo CT or MRI during screening and on study, as well as during follow-up as clinically necessary. Patients also undergo ECHO or nuclear study throughout the trial as clinically necessary. Patients undergo biopsies and blood sample collection on study.
Subprotocol V (cKIT exon 9, 11, 13, or 14 mutation)	Cytology Specimen Collection Procedure	Patients with cKIT exon 9, 11, 13, or 14 mutation receive sunitinib PO QD on days 1-28 of each cycle. Cycles repeat every 42 days in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo CT or MRI during screening and on study, as well as during follow-up as clinically necessary. Patients also undergo ECHO or nuclear study throughout the trial as clinically necessary. Patients undergo biopsies and blood sample collection on study.
Subprotocol V (cKIT exon 9, 11, 13, or 14 mutation)	Echocardiography	Patients with cKIT exon 9, 11, 13, or 14 mutation receive sunitinib PO QD on days 1-28 of each cycle. Cycles repeat every 42 days in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo CT or MRI during screening and on study, as well as during follow-up as clinically necessary. Patients also undergo ECHO or nuclear study throughout the trial as clinically necessary. Patients undergo biopsies and blood sample collection on study.
Subprotocol V (cKIT exon 9, 11, 13, or 14 mutation)	Laboratory Biomarker Analysis	Patients with cKIT exon 9, 11, 13, or 14 mutation receive sunitinib PO QD on days 1-28 of each cycle. Cycles repeat every 42 days in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo CT or MRI during screening and on study, as well as during follow-up as clinically necessary. Patients also undergo ECHO or nuclear study throughout the trial as clinically necessary. Patients undergo biopsies and blood sample collection on study.
Subprotocol V (cKIT exon 9, 11, 13, or 14 mutation)	Magnetic Resonance Imaging	Patients with cKIT exon 9, 11, 13, or 14 mutation receive sunitinib PO QD on days 1-28 of each cycle. Cycles repeat every 42 days in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo CT or MRI during screening and on study, as well as during follow-up as clinically necessary. Patients also undergo ECHO or nuclear study throughout the trial as clinically necessary. Patients undergo biopsies and blood sample collection on study.
Subprotocol V (cKIT exon 9, 11, 13, or 14 mutation)	Radionuclide Imaging	Patients with cKIT exon 9, 11, 13, or 14 mutation receive sunitinib PO QD on days 1-28 of each cycle. Cycles repeat every 42 days in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo CT or MRI during screening and on study, as well as during follow-up as clinically necessary. Patients also undergo ECHO or nuclear study throughout the trial as clinically necessary. Patients undergo biopsies and blood sample collection on study.
Subprotocol V (cKIT exon 9, 11, 13, or 14 mutation)	Sunitinib Malate	Patients with cKIT exon 9, 11, 13, or 14 mutation receive sunitinib PO QD on days 1-28 of each cycle. Cycles repeat every 42 days in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo CT or MRI during screening and on study, as well as during follow-up as clinically necessary. Patients also undergo ECHO or nuclear study throughout the trial as clinically necessary. Patients undergo biopsies and blood sample collection on study.
Subprotocol W (FGFR pathway aberrations)	Cytology Specimen Collection Procedure	Patients with FGFR1-3 mutation or translocation receive FGFR Inhibitor AZD4547 PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Subprotocol W (FGFR pathway aberrations)	Fexagratinib	Patients with FGFR1-3 mutation or translocation receive FGFR Inhibitor AZD4547 PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Subprotocol W (FGFR pathway aberrations)	Laboratory Biomarker Analysis	Patients with FGFR1-3 mutation or translocation receive FGFR Inhibitor AZD4547 PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Subprotocol X (DDR2 S768R, I638F, or L239R mutation)	Dasatinib	Patients with DDR2 S768R, I638F, or L239R mutation receive dasatinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Subprotocol X (DDR2 S768R, I638F, or L239R mutation)	Laboratory Biomarker Analysis	Patients with DDR2 S768R, I638F, or L239R mutation receive dasatinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Subprotocol Y (Akt mutation)	Cytology Specimen Collection Procedure	Patients with Akt mutation receive capivasertib PO BID on days 1-4, 8-11, 15-18, and 22-25. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Subprotocol Y (Akt mutation)	Laboratory Biomarker Analysis	Patients with Akt mutation receive capivasertib PO BID on days 1-4, 8-11, 15-18, and 22-25. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Subprotocol Z1A (NRAS mutation in codon 12, 13, or 61)	Binimetinib	Patients with NRAS mutation in codon 12, 13, or 61 receive binimetinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Subprotocol Z1A (NRAS mutation in codon 12, 13, or 61)	Cytology Specimen Collection Procedure	Patients with NRAS mutation in codon 12, 13, or 61 receive binimetinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Subprotocol Z1A (NRAS mutation in codon 12, 13, or 61)	Laboratory Biomarker Analysis	Patients with NRAS mutation in codon 12, 13, or 61 receive binimetinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Subprotocol Z1B (CCND1, 2, or 3 amplification with Rb by IHC)	Cytology Specimen Collection Procedure	Patients with CCND1, 2, or 3 amplification that have tumor Rb expression by IHC receive palbociclib PO QD for 21 days. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Subprotocol Z1B (CCND1, 2, or 3 amplification with Rb by IHC)	Laboratory Biomarker Analysis	Patients with CCND1, 2, or 3 amplification that have tumor Rb expression by IHC receive palbociclib PO QD for 21 days. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Subprotocol Z1B (CCND1, 2, or 3 amplification with Rb by IHC)	Palbociclib	Patients with CCND1, 2, or 3 amplification that have tumor Rb expression by IHC receive palbociclib PO QD for 21 days. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Subprotocol Z1C (CDK4 or CDK6 amplification and Rb protein)	Cytology Specimen Collection Procedure	Patients with CDK4 or CDK6 amplification and tumor Rb protein receive palbociclib PO QD on days 1-21. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Subprotocol Z1C (CDK4 or CDK6 amplification and Rb protein)	Laboratory Biomarker Analysis	Patients with CDK4 or CDK6 amplification and tumor Rb protein receive palbociclib PO QD on days 1-21. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Subprotocol Z1C (CDK4 or CDK6 amplification and Rb protein)	Palbociclib	Patients with CDK4 or CDK6 amplification and tumor Rb protein receive palbociclib PO QD on days 1-21. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Subprotocol Z1D (Loss of MLH1 or MSH2 by IHC)	Cytology Specimen Collection Procedure	Patients with mismatch repair deficiency (loss of MLH1 or MSH2 by IHC) receive nivolumab IV over 30 minutes on days 1 and 15 for 4 cycles and then on day 1 every 28 days. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Subprotocol Z1D (Loss of MLH1 or MSH2 by IHC)	Laboratory Biomarker Analysis	Patients with mismatch repair deficiency (loss of MLH1 or MSH2 by IHC) receive nivolumab IV over 30 minutes on days 1 and 15 for 4 cycles and then on day 1 every 28 days. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Subprotocol Z1D (Loss of MLH1 or MSH2 by IHC)	Nivolumab	Patients with mismatch repair deficiency (loss of MLH1 or MSH2 by IHC) receive nivolumab IV over 30 minutes on days 1 and 15 for 4 cycles and then on day 1 every 28 days. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Subprotocol Z1E (NTRK1, NTRK2 or NTRK3 gene fusion)	Biopsy	Patients with NTRK1, NTRK2, or NTRK3 gene fusion receive larotrectinib (LOXO-101) PO BID on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo CT or MRI during screening and on study, as well as during follow-up as clinically necessary. Patients also undergo biopsies and blood sample collection on study.
Subprotocol Z1E (NTRK1, NTRK2 or NTRK3 gene fusion)	Biospecimen Collection	Patients with NTRK1, NTRK2, or NTRK3 gene fusion receive larotrectinib (LOXO-101) PO BID on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo CT or MRI during screening and on study, as well as during follow-up as clinically necessary. Patients also undergo biopsies and blood sample collection on study.
Subprotocol Z1E (NTRK1, NTRK2 or NTRK3 gene fusion)	Computed Tomography	Patients with NTRK1, NTRK2, or NTRK3 gene fusion receive larotrectinib (LOXO-101) PO BID on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo CT or MRI during screening and on study, as well as during follow-up as clinically necessary. Patients also undergo biopsies and blood sample collection on study.
Subprotocol Z1E (NTRK1, NTRK2 or NTRK3 gene fusion)	Cytology Specimen Collection Procedure	Patients with NTRK1, NTRK2, or NTRK3 gene fusion receive larotrectinib (LOXO-101) PO BID on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo CT or MRI during screening and on study, as well as during follow-up as clinically necessary. Patients also undergo biopsies and blood sample collection on study.
Subprotocol Z1E (NTRK1, NTRK2 or NTRK3 gene fusion)	Laboratory Biomarker Analysis	Patients with NTRK1, NTRK2, or NTRK3 gene fusion receive larotrectinib (LOXO-101) PO BID on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo CT or MRI during screening and on study, as well as during follow-up as clinically necessary. Patients also undergo biopsies and blood sample collection on study.
Subprotocol Z1E (NTRK1, NTRK2 or NTRK3 gene fusion)	Larotrectinib	Patients with NTRK1, NTRK2, or NTRK3 gene fusion receive larotrectinib (LOXO-101) PO BID on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo CT or MRI during screening and on study, as well as during follow-up as clinically necessary. Patients also undergo biopsies and blood sample collection on study.
Subprotocol Z1E (NTRK1, NTRK2 or NTRK3 gene fusion)	Magnetic Resonance Imaging	Patients with NTRK1, NTRK2, or NTRK3 gene fusion receive larotrectinib (LOXO-101) PO BID on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo CT or MRI during screening and on study, as well as during follow-up as clinically necessary. Patients also undergo biopsies and blood sample collection on study.
Subprotocol Z1F (PIK3CA mutation)	Biopsy	Patients receive copanlisib IV over 1 hour on days 1, 8, and 15 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo tumor biopsies at screening and end of treatment as well as CT or MRI at baseline and repeated every 2 cycles for the first 26 cycles then every 3 cycles thereafter until progressive disease or start of another MATCH treatment step.
Subprotocol Z1F (PIK3CA mutation)	Computed Tomography	Patients receive copanlisib IV over 1 hour on days 1, 8, and 15 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo tumor biopsies at screening and end of treatment as well as CT or MRI at baseline and repeated every 2 cycles for the first 26 cycles then every 3 cycles thereafter until progressive disease or start of another MATCH treatment step.
Subprotocol Z1F (PIK3CA mutation)	Copanlisib	Patients receive copanlisib IV over 1 hour on days 1, 8, and 15 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo tumor biopsies at screening and end of treatment as well as CT or MRI at baseline and repeated every 2 cycles for the first 26 cycles then every 3 cycles thereafter until progressive disease or start of another MATCH treatment step.
Subprotocol Z1F (PIK3CA mutation)	Cytology Specimen Collection Procedure	Patients receive copanlisib IV over 1 hour on days 1, 8, and 15 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo tumor biopsies at screening and end of treatment as well as CT or MRI at baseline and repeated every 2 cycles for the first 26 cycles then every 3 cycles thereafter until progressive disease or start of another MATCH treatment step.
Subprotocol Z1F (PIK3CA mutation)	Magnetic Resonance Imaging	Patients receive copanlisib IV over 1 hour on days 1, 8, and 15 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo tumor biopsies at screening and end of treatment as well as CT or MRI at baseline and repeated every 2 cycles for the first 26 cycles then every 3 cycles thereafter until progressive disease or start of another MATCH treatment step.
Subprotocol Z1G (PTEN loss)	Copanlisib	Patients with PTEN loss receive copanlisib IV over 1 hour on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Subprotocol Z1G (PTEN loss)	Cytology Specimen Collection Procedure	Patients with PTEN loss receive copanlisib IV over 1 hour on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Subprotocol Z1G (PTEN loss)	Laboratory Biomarker Analysis	Patients with PTEN loss receive copanlisib IV over 1 hour on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Subprotocol Z1H (PTEN mutation)	Copanlisib	Patients with PTEN mutation receive copanlisib IV over 1 hour on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Subprotocol Z1H (PTEN mutation)	Cytology Specimen Collection Procedure	Patients with PTEN mutation receive copanlisib IV over 1 hour on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Subprotocol Z1H (PTEN mutation)	Laboratory Biomarker Analysis	Patients with PTEN mutation receive copanlisib IV over 1 hour on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Subprotocol Z1I (BRCA1 or BRCA2 gene mutation)	Adavosertib	Patients with BRCA1 or BRCA2 gene mutation receive adavosertib PO QD for 5 days for 2 weeks. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
Subprotocol Z1I (BRCA1 or BRCA2 gene mutation)	Cytology Specimen Collection Procedure	Patients with BRCA1 or BRCA2 gene mutation receive adavosertib PO QD for 5 days for 2 weeks. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
Subprotocol Z1I (BRCA1 or BRCA2 gene mutation)	Laboratory Biomarker Analysis	Patients with BRCA1 or BRCA2 gene mutation receive adavosertib PO QD for 5 days for 2 weeks. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
Subprotocol Z1K (AKT mutation)	Cytology Specimen Collection Procedure	Patients receive ipatasertib PO QD. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Subprotocol Z1K (AKT mutation)	Ipatasertib	Patients receive ipatasertib PO QD. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Subprotocol Z1K (AKT mutation)	Laboratory Biomarker Analysis	Patients receive ipatasertib PO QD. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Subprotocol Z1L (BRAF fusion, aberration or non-V600 mutation)	Cytology Specimen Collection Procedure	Patients with a BRAF non-V600 mutation or BRAF fusion, or another BRAF aberration receive ulixertinib (BVD-523FB) PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Subprotocol Z1L (BRAF fusion, aberration or non-V600 mutation)	Laboratory Biomarker Analysis	Patients with a BRAF non-V600 mutation or BRAF fusion, or another BRAF aberration receive ulixertinib (BVD-523FB) PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Subprotocol Z1M (LAG-3 expression >= 1%)	Cytology Specimen Collection Procedure	Patients receive nivolumab IV over 30 minutes and relatlimab IV over 30 minutes on day 1.Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Subprotocol Z1M (LAG-3 expression >= 1%)	Laboratory Biomarker Analysis	Patients receive nivolumab IV over 30 minutes and relatlimab IV over 30 minutes on day 1.Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Subprotocol Z1M (LAG-3 expression >= 1%)	Nivolumab	Patients receive nivolumab IV over 30 minutes and relatlimab IV over 30 minutes on day 1.Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Subprotocol Z1M (LAG-3 expression >= 1%)	Relatlimab	Patients receive nivolumab IV over 30 minutes and relatlimab IV over 30 minutes on day 1.Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Subprotocol U (NF2 inactivating mutation)	Defactinib	Patients with NF2 inactivating mutation receive defactinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Subprotocol I (PIK3CA mutation)	Taselisib	Patients with PIK3CA mutation without RAS mutation or PTEN loss receive taselisib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Subprotocol Z1L (BRAF fusion, aberration or non-V600 mutation)	Ulixertinib	Patients with a BRAF non-V600 mutation or BRAF fusion, or another BRAF aberration receive ulixertinib (BVD-523FB) PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Subprotocol Y (Akt mutation)	Capivasertib	Patients with Akt mutation receive capivasertib PO BID on days 1-4, 8-11, 15-18, and 22-25. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Primary Outcome Measures

Name	Time	Method
Objective response rate (ORR)	Up to 3 years	ORR is defined as the percentage of patients whose tumors have a complete or partial response to treatment among analyzable patients. Objective response is defined consistent with Response Evaluation Criteria in Solid Tumors version 1.1, the Cheson (2014) criteria for lymphoma patients, and the Response Assessment in Neuro-Oncology criteria for glioblastoma patients. 90% two-sided confidence interval is calculated for ORR. For the purposes of this study, patients should be re-evaluated for response: * For treatments given in 21 day (3 week) cycles: every 3 cycles (9 weeks) for the first 33 cycles, and every 4 cycles thereafter (12 weeks) * For treatments given in 28 day (4 week) cycles: every 2 cycles (8 weeks) for the first 26 cycles, and every three cycles thereafter (12 weeks) * For treatments given in 42 day (6 week) cycles: every 2 cycles (12 weeks)

Secondary Outcome Measures

Name	Time	Method
Overall survival (OS)	From start of treatment on that step until death, or censored at the date of last contact, assessed up to 3 years	Will be evaluated specifically for each drug (or step). OS will be estimated using the Kaplan-Meier method.
6-month progression free survival (PFS) rate	From start of treatment on that step until determination of disease progression or death from any cause, censored at the date of last disease assessment for patients who have not progressed, assessed at 6 months	Progression free survival is defined as time from treatment start date to date of progression or death from any cause, whichever occurs first. Disease progression was evaluated using the Response Evaluation Criteria in Solid Tumors version 1.1, the Cheson (2014) criteria for lymphoma patients, and the Response Assessment in Neuro-Oncology criteria for glioblastoma patients. Please refer to the protocol for detailed definitions of disease progression. 6 month PFS rate was estimated using the Kaplan-Meier method, which can provide a point estimate for any specific time point.
Progression free survival	From start of treatment on that step until determination of disease progression or death from any cause, censored at the date of last disease assessment for patients who have not progressed, assessed up to 3 years	PFS was defined as time from treatment start date to date of disease progression or death from any causes, whichever occurred first. Median PFS was estimated using the Kaplan-Meier method. Disease progression was evaluated using the Response Evaluation Criteria in Solid Tumors version 1.1, the Cheson (2014) criteria for lymphoma patients, and the Response Assessment in Neuro-Oncology criteria for glioblastoma patients. Please refer to the protocol for detailed definitions of disease progression.

Trial Locations

Locations (1419): University of Alabama at Birmingham Cancer Center
🇺🇸
Birmingham, Alabama, United States
Thomas Hospital
🇺🇸
Fairhope, Alabama, United States
Mobile Infirmary Medical Center
🇺🇸
Mobile, Alabama, United States
University of South Alabama Mitchell Cancer Institute
🇺🇸
Mobile, Alabama, United States
Anchorage Associates in Radiation Medicine
🇺🇸
Anchorage, Alaska, United States
Anchorage Radiation Therapy Center
🇺🇸
Anchorage, Alaska, United States
Alaska Breast Care and Surgery LLC
🇺🇸
Anchorage, Alaska, United States
Alaska Oncology and Hematology LLC
🇺🇸
Anchorage, Alaska, United States
Alaska Regional Hospital
🇺🇸
Anchorage, Alaska, United States
Alaska Women's Cancer Care
🇺🇸
Anchorage, Alaska, United States
Anchorage Oncology Centre
🇺🇸
Anchorage, Alaska, United States
Katmai Oncology Group
🇺🇸
Anchorage, Alaska, United States
Providence Alaska Medical Center
🇺🇸
Anchorage, Alaska, United States
Fairbanks Memorial Hospital
🇺🇸
Fairbanks, Alaska, United States
CTCA at Western Regional Medical Center
🇺🇸
Goodyear, Arizona, United States
Kingman Regional Medical Center
🇺🇸
Kingman, Arizona, United States
Cancer Center at Saint Joseph's
🇺🇸
Phoenix, Arizona, United States
Saint Joseph's Hospital and Medical Center
🇺🇸
Phoenix, Arizona, United States
Mayo Clinic Hospital in Arizona
🇺🇸
Phoenix, Arizona, United States
Mayo Clinic in Arizona
🇺🇸
Scottsdale, Arizona, United States
Mercy Hospital Fort Smith
🇺🇸
Fort Smith, Arkansas, United States
CHI Saint Vincent Cancer Center Hot Springs
🇺🇸
Hot Springs, Arkansas, United States
NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro
🇺🇸
Jonesboro, Arkansas, United States
University of Arkansas for Medical Sciences
🇺🇸
Little Rock, Arkansas, United States
Kaiser Permanente-Anaheim
🇺🇸
Anaheim, California, United States
Kaiser Permanente-Deer Valley Medical Center
🇺🇸
Antioch, California, United States
Mission Hope Medical Oncology - Arroyo Grande
🇺🇸
Arroyo Grande, California, United States
PCR Oncology
🇺🇸
Arroyo Grande, California, United States
Sutter Auburn Faith Hospital
🇺🇸
Auburn, California, United States
Sutter Cancer Centers Radiation Oncology Services-Auburn
🇺🇸
Auburn, California, United States
AIS Cancer Center at San Joaquin Community Hospital
🇺🇸
Bakersfield, California, United States
Kaiser Permanente-Baldwin Park
🇺🇸
Baldwin Park, California, United States
Kaiser Permanente-Bellflower
🇺🇸
Bellflower, California, United States
Alta Bates Summit Medical Center-Herrick Campus
🇺🇸
Berkeley, California, United States
Providence Saint Joseph Medical Center/Disney Family Cancer Center
🇺🇸
Burbank, California, United States
Mills-Peninsula Medical Center
🇺🇸
Burlingame, California, United States
Sutter Cancer Centers Radiation Oncology Services-Cameron Park
🇺🇸
Cameron Park, California, United States
Eden Hospital Medical Center
🇺🇸
Castro Valley, California, United States
Community Cancer Institute
🇺🇸
Clovis, California, United States
University Oncology Associates
🇺🇸
Clovis, California, United States
John Muir Medical Center-Concord
🇺🇸
Concord, California, United States
City of Hope Corona
🇺🇸
Corona, California, United States
UC Irvine Health Cancer Center-Newport
🇺🇸
Costa Mesa, California, United States
Sutter Davis Hospital
🇺🇸
Davis, California, United States
City of Hope Comprehensive Cancer Center
🇺🇸
Duarte, California, United States
Epic Care-Dublin
🇺🇸
Dublin, California, United States
Kaiser Permanente Dublin
🇺🇸
Dublin, California, United States
Bay Area Breast Surgeons Inc
🇺🇸
Emeryville, California, United States
Epic Care Partners in Cancer Care
🇺🇸
Emeryville, California, United States
Kaiser Permanente-Fontana
🇺🇸
Fontana, California, United States
Kaiser Permanente-Fremont
🇺🇸
Fremont, California, United States
Palo Alto Medical Foundation-Fremont
🇺🇸
Fremont, California, United States
Fresno Cancer Center
🇺🇸
Fresno, California, United States
Kaiser Permanente-Fresno
🇺🇸
Fresno, California, United States
Saint Jude Medical Center
🇺🇸
Fullerton, California, United States
Marin Cancer Care Inc
🇺🇸
Greenbrae, California, United States
Marin General Hospital
🇺🇸
Greenbrae, California, United States
Kaiser Permanente South Bay
🇺🇸
Harbor City, California, United States
Kaiser Permanente-Irvine
🇺🇸
Irvine, California, United States
UC San Diego Moores Cancer Center
🇺🇸
La Jolla, California, United States
Loma Linda University Medical Center
🇺🇸
Loma Linda, California, United States
Kaiser Permanente Los Angeles Medical Center
🇺🇸
Los Angeles, California, United States
Los Angeles General Medical Center
🇺🇸
Los Angeles, California, United States
USC / Norris Comprehensive Cancer Center
🇺🇸
Los Angeles, California, United States
Kaiser Permanente West Los Angeles
🇺🇸
Los Angeles, California, United States
Cedars Sinai Medical Center
🇺🇸
Los Angeles, California, United States
Contra Costa Regional Medical Center
🇺🇸
Martinez, California, United States
Fremont - Rideout Cancer Center
🇺🇸
Marysville, California, United States
Memorial Medical Center
🇺🇸
Modesto, California, United States
Kaiser Permanente-Modesto
🇺🇸
Modesto, California, United States
Community Hospital of Monterey Peninsula
🇺🇸
Monterey, California, United States
Pacific Cancer Care-Monterey
🇺🇸
Monterey, California, United States
Palo Alto Medical Foundation-Camino Division
🇺🇸
Mountain View, California, United States
Palo Alto Medical Foundation-Gynecologic Oncology
🇺🇸
Mountain View, California, United States
USC Norris Oncology/Hematology-Newport Beach
🇺🇸
Newport Beach, California, United States
Sutter Cancer Research Consortium
🇺🇸
Novato, California, United States
Alta Bates Summit Medical Center - Summit Campus
🇺🇸
Oakland, California, United States
Bay Area Tumor Institute
🇺🇸
Oakland, California, United States
Kaiser Permanente Oakland-Broadway
🇺🇸
Oakland, California, United States
Kaiser Permanente-Oakland
🇺🇸
Oakland, California, United States
Kaiser Permanente-Ontario
🇺🇸
Ontario, California, United States
Saint Joseph Hospital - Orange
🇺🇸
Orange, California, United States
UC Irvine Health/Chao Family Comprehensive Cancer Center
🇺🇸
Orange, California, United States
Desert Regional Medical Center
🇺🇸
Palm Springs, California, United States
Palo Alto Medical Foundation Health Care
🇺🇸
Palo Alto, California, United States
Stanford Cancer Institute Palo Alto
🇺🇸
Palo Alto, California, United States
VA Palo Alto Health Care System
🇺🇸
Palo Alto, California, United States
Kaiser Permanente - Panorama City
🇺🇸
Panorama City, California, United States
Keck Medical Center of USC Pasadena
🇺🇸
Pasadena, California, United States
Kaiser Permanente-Rancho Cordova Cancer Center
🇺🇸
Rancho Cordova, California, United States
Eisenhower Medical Center
🇺🇸
Rancho Mirage, California, United States
Kaiser Permanente- Marshall Medical Offices
🇺🇸
Redwood City, California, United States
Kaiser Permanente-Redwood City
🇺🇸
Redwood City, California, United States
Kaiser Permanente-Richmond
🇺🇸
Richmond, California, United States
Kaiser Permanente-Riverside
🇺🇸
Riverside, California, United States
Rohnert Park Cancer Center
🇺🇸
Rohnert Park, California, United States
Kaiser Permanente-Roseville
🇺🇸
Roseville, California, United States
Sutter Cancer Centers Radiation Oncology Services-Roseville
🇺🇸
Roseville, California, United States
Sutter Roseville Medical Center
🇺🇸
Roseville, California, United States
The Permanente Medical Group-Roseville Radiation Oncology
🇺🇸
Roseville, California, United States
Kaiser Permanente Downtown Commons
🇺🇸
Sacramento, California, United States
Mercy Cancer Center - Sacramento
🇺🇸
Sacramento, California, United States
Sutter Medical Center Sacramento
🇺🇸
Sacramento, California, United States
University of California Davis Comprehensive Cancer Center
🇺🇸
Sacramento, California, United States
Kaiser Permanente-South Sacramento
🇺🇸
Sacramento, California, United States
South Sacramento Cancer Center
🇺🇸
Sacramento, California, United States
Kaiser Permanente Sacramento Medical Center
🇺🇸
Sacramento, California, United States
Saint Helena Hospital
🇺🇸
Saint Helena, California, United States
UC San Diego Medical Center - Hillcrest
🇺🇸
San Diego, California, United States
Kaiser Permanente-San Diego Mission
🇺🇸
San Diego, California, United States
Kaiser Permanente-San Diego Zion
🇺🇸
San Diego, California, United States
Rady Children's Hospital - San Diego
🇺🇸
San Diego, California, United States
Sharp Memorial Hospital
🇺🇸
San Diego, California, United States
Naval Medical Center -San Diego
🇺🇸
San Diego, California, United States
California Pacific Medical Center-Pacific Campus
🇺🇸
San Francisco, California, United States
Kaiser Permanente-San Francisco
🇺🇸
San Francisco, California, United States
Kaiser Permanente-Santa Teresa-San Jose
🇺🇸
San Jose, California, United States
Kaiser Permanente San Leandro
🇺🇸
San Leandro, California, United States
Pacific Central Coast Health Center-San Luis Obispo
🇺🇸
San Luis Obispo, California, United States
Kaiser Permanente-San Marcos
🇺🇸
San Marcos, California, United States
Mills Health Center
🇺🇸
San Mateo, California, United States
Kaiser Permanente-San Rafael
🇺🇸
San Rafael, California, United States
Kaiser San Rafael-Gallinas
🇺🇸
San Rafael, California, United States
Kaiser Permanente Medical Center - Santa Clara
🇺🇸
Santa Clara, California, United States
Palo Alto Medical Foundation-Santa Cruz
🇺🇸
Santa Cruz, California, United States
Mission Hope Medical Oncology - Santa Maria
🇺🇸
Santa Maria, California, United States
Kaiser Permanente-Santa Rosa
🇺🇸
Santa Rosa, California, United States
Sutter Pacific Medical Foundation
🇺🇸
Santa Rosa, California, United States
Kaiser Permanente Cancer Treatment Center
🇺🇸
South San Francisco, California, United States
Kaiser Permanente-South San Francisco
🇺🇸
South San Francisco, California, United States
Saint Joseph's Medical Center
🇺🇸
Stockton, California, United States
Kaiser Permanente-Stockton
🇺🇸
Stockton, California, United States
Palo Alto Medical Foundation-Sunnyvale
🇺🇸
Sunnyvale, California, United States
Gene Upshaw Memorial Tahoe Forest Cancer Center
🇺🇸
Truckee, California, United States
City of Hope Upland
🇺🇸
Upland, California, United States
Kaiser Permanente Medical Center-Vacaville
🇺🇸
Vacaville, California, United States
Kaiser Permanente-Vallejo
🇺🇸
Vallejo, California, United States
Sutter Solano Medical Center/Cancer Center
🇺🇸
Vallejo, California, United States
Kaiser Permanente-Walnut Creek
🇺🇸
Walnut Creek, California, United States
Epic Care Cyberknife Center
🇺🇸
Walnut Creek, California, United States
John Muir Medical Center-Walnut Creek
🇺🇸
Walnut Creek, California, United States
City of Hope West Covina
🇺🇸
West Covina, California, United States
Presbyterian Intercommunity Hospital
🇺🇸
Whittier, California, United States
Kaiser Permanente-Woodland Hills
🇺🇸
Woodland Hills, California, United States
Woodland Memorial Hospital
🇺🇸
Woodland, California, United States
Rocky Mountain Cancer Centers-Aurora
🇺🇸
Aurora, Colorado, United States
The Medical Center of Aurora
🇺🇸
Aurora, Colorado, United States
UCHealth University of Colorado Hospital
🇺🇸
Aurora, Colorado, United States
Boulder Community Hospital
🇺🇸
Boulder, Colorado, United States
Boulder Community Foothills Hospital
🇺🇸
Boulder, Colorado, United States
Rocky Mountain Cancer Centers-Boulder
🇺🇸
Boulder, Colorado, United States
Rocky Mountain Cancer Centers - Centennial
🇺🇸
Centennial, Colorado, United States
Penrose-Saint Francis Healthcare
🇺🇸
Colorado Springs, Colorado, United States
Rocky Mountain Cancer Centers-Penrose
🇺🇸
Colorado Springs, Colorado, United States
UCHealth Memorial Hospital Central
🇺🇸
Colorado Springs, Colorado, United States
Memorial Hospital North
🇺🇸
Colorado Springs, Colorado, United States
Saint Francis Cancer Center
🇺🇸
Greenville, South Carolina, United States
Cancer Center of Colorado at Sloan's Lake
🇺🇸
Denver, Colorado, United States
Denver Health Medical Center
🇺🇸
Denver, Colorado, United States
Kaiser Permanente-Franklin
🇺🇸
Denver, Colorado, United States
National Jewish Health-Main Campus
🇺🇸
Denver, Colorado, United States
The Women's Imaging Center
🇺🇸
Denver, Colorado, United States
Porter Adventist Hospital
🇺🇸
Denver, Colorado, United States
Colorado Blood Cancer Institute
🇺🇸
Denver, Colorado, United States
Presbyterian - Saint Lukes Medical Center - Health One
🇺🇸
Denver, Colorado, United States
Rocky Mountain Cancer Centers-Midtown
🇺🇸
Denver, Colorado, United States
Saint Joseph Hospital - Cancer Centers of Colorado
🇺🇸
Denver, Colorado, United States
Rocky Mountain Cancer Centers-Rose
🇺🇸
Denver, Colorado, United States
Rose Medical Center
🇺🇸
Denver, Colorado, United States
Mercy Medical Center
🇺🇸
Springfield, Massachusetts, United States
Southwest Oncology PC
🇺🇸
Durango, Colorado, United States
Mountain Blue Cancer Care Center - Swedish
🇺🇸
Englewood, Colorado, United States
Rocky Mountain Cancer Centers - Swedish
🇺🇸
Englewood, Colorado, United States
Swedish Medical Center
🇺🇸
Englewood, Colorado, United States
Poudre Valley Hospital
🇺🇸
Fort Collins, Colorado, United States
Mountain Blue Cancer Care Center
🇺🇸
Golden, Colorado, United States
National Jewish Health-Western Hematology Oncology
🇺🇸
Golden, Colorado, United States
Saint Mary's Hospital and Regional Medical Center
🇺🇸
Grand Junction, Colorado, United States
Grand Valley Oncology
🇺🇸
Grand Junction, Colorado, United States
Banner North Colorado Medical Center
🇺🇸
Greeley, Colorado, United States
Rocky Mountain Cancer Centers-Greenwood Village
🇺🇸
Greenwood Village, Colorado, United States
Good Samaritan Hospital - Cancer Centers of Colorado
🇺🇸
Lafayette, Colorado, United States
Kaiser Permanente-Rock Creek
🇺🇸
Lafayette, Colorado, United States
Rocky Mountain Cancer Centers-Lakewood
🇺🇸
Lakewood, Colorado, United States
Saint Anthony Hospital
🇺🇸
Lakewood, Colorado, United States
Rocky Mountain Cancer Centers-Littleton
🇺🇸
Littleton, Colorado, United States
Littleton Adventist Hospital
🇺🇸
Littleton, Colorado, United States
Kaiser Permanente-Lone Tree
🇺🇸
Lone Tree, Colorado, United States
Rocky Mountain Cancer Centers-Sky Ridge
🇺🇸
Lone Tree, Colorado, United States
Sky Ridge Medical Center
🇺🇸
Lone Tree, Colorado, United States
Longmont United Hospital
🇺🇸
Longmont, Colorado, United States
Rocky Mountain Cancer Centers-Longmont
🇺🇸
Longmont, Colorado, United States
Banner McKee Medical Center
🇺🇸
Loveland, Colorado, United States
Parker Adventist Hospital
🇺🇸
Parker, Colorado, United States
Rocky Mountain Cancer Centers-Parker
🇺🇸
Parker, Colorado, United States
Saint Mary Corwin Medical Center
🇺🇸
Pueblo, Colorado, United States
Rocky Mountain Cancer Centers - Pueblo
🇺🇸
Pueblo, Colorado, United States
National Jewish Health-Northern Hematology Oncology
🇺🇸
Thornton, Colorado, United States
Rocky Mountain Cancer Centers-Thornton
🇺🇸
Thornton, Colorado, United States
Intermountain Health Lutheran Hospital
🇺🇸
Wheat Ridge, Colorado, United States
Smilow Cancer Hospital-Derby Care Center
🇺🇸
Derby, Connecticut, United States
Smilow Cancer Hospital Care Center-Fairfield
🇺🇸
Fairfield, Connecticut, United States
Smilow Cancer Hospital Care Center at Glastonbury
🇺🇸
Glastonbury, Connecticut, United States
Smilow Cancer Hospital Care Center at Greenwich
🇺🇸
Greenwich, Connecticut, United States
Smilow Cancer Hospital Care Center - Guilford
🇺🇸
Guilford, Connecticut, United States
Smilow Cancer Hospital Care Center at Saint Francis
🇺🇸
Hartford, Connecticut, United States
Smilow Cancer Center/Yale-New Haven Hospital
🇺🇸
New Haven, Connecticut, United States
Yale University
🇺🇸
New Haven, Connecticut, United States
Yale-New Haven Hospital North Haven Medical Center
🇺🇸
North Haven, Connecticut, United States
Eastern Connecticut Hematology and Oncology Associates
🇺🇸
Norwich, Connecticut, United States
Smilow Cancer Hospital-Orange Care Center
🇺🇸
Orange, Connecticut, United States
Stamford Hospital/Bennett Cancer Center
🇺🇸
Stamford, Connecticut, United States
Smilow Cancer Hospital-Torrington Care Center
🇺🇸
Torrington, Connecticut, United States
Smilow Cancer Hospital Care Center-Trumbull
🇺🇸
Trumbull, Connecticut, United States
Smilow Cancer Hospital-Waterbury Care Center
🇺🇸
Waterbury, Connecticut, United States
Smilow Cancer Hospital Care Center - Waterford
🇺🇸
Waterford, Connecticut, United States
Veterans Affairs Connecticut Healthcare System-West Haven Campus
🇺🇸
West Haven, Connecticut, United States
Beebe Medical Center
🇺🇸
Lewes, Delaware, United States
Beebe South Coastal Health Campus
🇺🇸
Millville, Delaware, United States
Delaware Clinical and Laboratory Physicians PA
🇺🇸
Newark, Delaware, United States
Helen F Graham Cancer Center
🇺🇸
Newark, Delaware, United States
Medical Oncology Hematology Consultants PA
🇺🇸
Newark, Delaware, United States
Christiana Care Health System-Christiana Hospital
🇺🇸
Newark, Delaware, United States
Beebe Health Campus
🇺🇸
Rehoboth Beach, Delaware, United States
TidalHealth Nanticoke / Allen Cancer Center
🇺🇸
Seaford, Delaware, United States
Christiana Care Health System-Wilmington Hospital
🇺🇸
Wilmington, Delaware, United States
MedStar Georgetown University Hospital
🇺🇸
Washington, District of Columbia, United States
MedStar Washington Hospital Center
🇺🇸
Washington, District of Columbia, United States
Sibley Memorial Hospital
🇺🇸
Washington, District of Columbia, United States
Mount Sinai Comprehensive Cancer Center at Aventura
🇺🇸
Aventura, Florida, United States
UM Sylvester Comprehensive Cancer Center at Coral Gables
🇺🇸
Coral Gables, Florida, United States
UM Sylvester Comprehensive Cancer Center at Coral Springs
🇺🇸
Coral Springs, Florida, United States
Broward Health North
🇺🇸
Deerfield Beach, Florida, United States
UM Sylvester Comprehensive Cancer Center at Deerfield Beach
🇺🇸
Deerfield Beach, Florida, United States
Holy Cross Hospital
🇺🇸
Silver Spring, Maryland, United States
Broward Health Medical Center
🇺🇸
Fort Lauderdale, Florida, United States
University of Florida Health Science Center - Gainesville
🇺🇸
Gainesville, Florida, United States
Memorial Regional Hospital/Joe DiMaggio Children's Hospital
🇺🇸
Hollywood, Florida, United States
UM Sylvester Comprehensive Cancer Center at Hollywood
🇺🇸
Hollywood, Florida, United States
Mayo Clinic in Florida
🇺🇸
Jacksonville, Florida, United States
The Watson Clinic
🇺🇸
Lakeland, Florida, United States
Mount Sinai Medical Center
🇺🇸
Miami Beach, Florida, United States
University of Miami Miller School of Medicine-Sylvester Cancer Center
🇺🇸
Miami, Florida, United States
Miami Cancer Institute
🇺🇸
Miami, Florida, United States
UM Sylvester Comprehensive Cancer Center at Kendall
🇺🇸
Miami, Florida, United States
Health Central
🇺🇸
Ocoee, Florida, United States
Orlando Health Cancer Institute
🇺🇸
Orlando, Florida, United States
Memorial Hospital West
🇺🇸
Pembroke Pines, Florida, United States
UM Sylvester Comprehensive Cancer Center at Plantation
🇺🇸
Plantation, Florida, United States
Saint Joseph's Hospital/Children's Hospital-Tampa
🇺🇸
Tampa, Florida, United States
Moffitt Cancer Center
🇺🇸
Tampa, Florida, United States
Indian River Medical Center
🇺🇸
Vero Beach, Florida, United States
University Cancer and Blood Center LLC
🇺🇸
Athens, Georgia, United States
Emory University Hospital Midtown
🇺🇸
Atlanta, Georgia, United States
Piedmont Hospital
🇺🇸
Atlanta, Georgia, United States
Emory University Hospital/Winship Cancer Institute
🇺🇸
Atlanta, Georgia, United States
Emory Saint Joseph's Hospital
🇺🇸
Atlanta, Georgia, United States
Northside Hospital
🇺🇸
Atlanta, Georgia, United States
Augusta University Medical Center
🇺🇸
Augusta, Georgia, United States
Northeast Georgia Medical Center Braselton
🇺🇸
Braselton, Georgia, United States
John B Amos Cancer Center
🇺🇸
Columbus, Georgia, United States
Northside Hospital-Forsyth
🇺🇸
Cumming, Georgia, United States
Dekalb Medical Center
🇺🇸
Decatur, Georgia, United States
Northside Hospital - Duluth
🇺🇸
Duluth, Georgia, United States
Northeast Georgia Medical Center-Gainesville
🇺🇸
Gainesville, Georgia, United States
The Longstreet Clinic - Gainesville
🇺🇸
Gainesville, Georgia, United States
Northside Hospital - Gwinnett
🇺🇸
Lawrenceville, Georgia, United States
Atrium Health Navicent
🇺🇸
Macon, Georgia, United States
Central Georgia Gynecologic Oncology
🇺🇸
Macon, Georgia, United States
CTCA at Southeastern Regional Medical Center
🇺🇸
Newnan, Georgia, United States
Harbin Clinic Medical Oncology and Clinical Research
🇺🇸
Rome, Georgia, United States
Low Country Cancer Care
🇺🇸
Savannah, Georgia, United States
Memorial Health University Medical Center
🇺🇸
Savannah, Georgia, United States
Summit Cancer Care-Memorial
🇺🇸
Savannah, Georgia, United States
Lewis Cancer and Research Pavilion at Saint Joseph's/Candler
🇺🇸
Savannah, Georgia, United States
Summit Cancer Care-Candler
🇺🇸
Savannah, Georgia, United States
Suburban Hematology Oncology Associates - Snellville
🇺🇸
Snellville, Georgia, United States
Lewis Hall Singletary Oncology Center
🇺🇸
Thomasville, Georgia, United States
South Georgia Medical Center/Pearlman Cancer Center
🇺🇸
Valdosta, Georgia, United States
Hawaii Cancer Care - Westridge
🇺🇸
'Aiea, Hawaii, United States
Pali Momi Medical Center
🇺🇸
'Aiea, Hawaii, United States
Queen's Cancer Center - Pearlridge
🇺🇸
'Aiea, Hawaii, United States
Straub Pearlridge Clinic
🇺🇸
'Aiea, Hawaii, United States
The Cancer Center of Hawaii-Pali Momi
🇺🇸
'Aiea, Hawaii, United States
The Queen's Medical Center - West Oahu
🇺🇸
'Ewa Beach, Hawaii, United States
Hawaii Cancer Care Inc - Waterfront Plaza
🇺🇸
Honolulu, Hawaii, United States
Island Urology
🇺🇸
Honolulu, Hawaii, United States
Queen's Cancer Cenrer - POB I
🇺🇸
Honolulu, Hawaii, United States
Queen's Medical Center
🇺🇸
Honolulu, Hawaii, United States
Straub Clinic and Hospital
🇺🇸
Honolulu, Hawaii, United States
University of Hawaii Cancer Center
🇺🇸
Honolulu, Hawaii, United States
Hawaii Cancer Care Inc-Liliha
🇺🇸
Honolulu, Hawaii, United States
Hawaii Diagnostic Radiology Services LLC
🇺🇸
Honolulu, Hawaii, United States
Kuakini Medical Center
🇺🇸
Honolulu, Hawaii, United States
Queen's Cancer Center - Kuakini
🇺🇸
Honolulu, Hawaii, United States
The Cancer Center of Hawaii-Liliha
🇺🇸
Honolulu, Hawaii, United States
Kaiser Permanente Moanalua Medical Center
🇺🇸
Honolulu, Hawaii, United States
Kapiolani Medical Center for Women and Children
🇺🇸
Honolulu, Hawaii, United States
Straub Medical Center - Kahului Clinic
🇺🇸
Kahului, Hawaii, United States
Castle Medical Center
🇺🇸
Kailua, Hawaii, United States
Wilcox Memorial Hospital and Kauai Medical Clinic
🇺🇸
Lihue, Hawaii, United States
Saint Alphonsus Cancer Care Center-Boise
🇺🇸
Boise, Idaho, United States
Saint Luke's Cancer Institute - Boise
🇺🇸
Boise, Idaho, United States
Saint Alphonsus Cancer Care Center-Caldwell
🇺🇸
Caldwell, Idaho, United States
Kootenai Health - Coeur d'Alene
🇺🇸
Coeur d'Alene, Idaho, United States
Walter Knox Memorial Hospital
🇺🇸
Emmett, Idaho, United States
Saint Luke's Cancer Institute - Fruitland
🇺🇸
Fruitland, Idaho, United States
Idaho Urologic Institute-Meridian
🇺🇸
Meridian, Idaho, United States
Saint Luke's Cancer Institute - Meridian
🇺🇸
Meridian, Idaho, United States
Saint Alphonsus Cancer Care Center-Nampa
🇺🇸
Nampa, Idaho, United States
Saint Luke's Cancer Institute - Nampa
🇺🇸
Nampa, Idaho, United States
Kootenai Clinic Cancer Services - Post Falls
🇺🇸
Post Falls, Idaho, United States
Kootenai Clinic Cancer Services - Sandpoint
🇺🇸
Sandpoint, Idaho, United States
Saint Luke's Cancer Institute - Twin Falls
🇺🇸
Twin Falls, Idaho, United States
OSF Saint Anthony's Health Center
🇺🇸
Alton, Illinois, United States
Rush - Copley Medical Center
🇺🇸
Aurora, Illinois, United States
OSF Saint Joseph Medical Center
🇺🇸
Bloomington, Illinois, United States
Illinois CancerCare-Bloomington
🇺🇸
Bloomington, Illinois, United States
Illinois CancerCare-Canton
🇺🇸
Canton, Illinois, United States
Memorial Hospital of Carbondale
🇺🇸
Carbondale, Illinois, United States
SIH Cancer Institute
🇺🇸
Carterville, Illinois, United States
Illinois CancerCare-Carthage
🇺🇸
Carthage, Illinois, United States
Centralia Oncology Clinic
🇺🇸
Centralia, Illinois, United States
Mount Sinai Hospital Medical Center
🇺🇸
Chicago, Illinois, United States
Northwestern University
🇺🇸
Chicago, Illinois, United States
John H Stroger Jr Hospital of Cook County
🇺🇸
Chicago, Illinois, United States
Rush University Medical Center
🇺🇸
Chicago, Illinois, United States
University of Illinois
🇺🇸
Chicago, Illinois, United States
Swedish Covenant Hospital
🇺🇸
Chicago, Illinois, United States
University of Chicago Comprehensive Cancer Center
🇺🇸
Chicago, Illinois, United States
Advocate Illinois Masonic Medical Center
🇺🇸
Chicago, Illinois, United States
AMG Crystal Lake - Oncology
🇺🇸
Crystal Lake, Illinois, United States
Carle at The Riverfront
🇺🇸
Danville, Illinois, United States
Cancer Care Specialists of Illinois - Decatur
🇺🇸
Decatur, Illinois, United States
Decatur Memorial Hospital
🇺🇸
Decatur, Illinois, United States
Northwestern Medicine Cancer Center Kishwaukee
🇺🇸
DeKalb, Illinois, United States
Illinois CancerCare-Dixon
🇺🇸
Dixon, Illinois, United States
Carle Physician Group-Effingham
🇺🇸
Effingham, Illinois, United States
Crossroads Cancer Center
🇺🇸
Effingham, Illinois, United States
Ascension Alexian Brothers - Elk Grove Village
🇺🇸
Elk Grove Village, Illinois, United States
Elmhurst Memorial Hospital
🇺🇸
Elmhurst, Illinois, United States
Illinois CancerCare-Eureka
🇺🇸
Eureka, Illinois, United States
NorthShore University HealthSystem-Evanston Hospital
🇺🇸
Evanston, Illinois, United States
Saint Francis Hospital
🇺🇸
Federal Way, Washington, United States
Illinois CancerCare-Galesburg
🇺🇸
Galesburg, Illinois, United States
Western Illinois Cancer Treatment Center
🇺🇸
Galesburg, Illinois, United States
Northwestern Medicine Cancer Center Delnor
🇺🇸
Geneva, Illinois, United States
NorthShore University HealthSystem-Glenbrook Hospital
🇺🇸
Glenview, Illinois, United States
Ingalls Memorial Hospital
🇺🇸
Harvey, Illinois, United States
NorthShore University HealthSystem-Highland Park Hospital
🇺🇸
Highland Park, Illinois, United States
Duly Health and Care Joliet
🇺🇸
Joliet, Illinois, United States
Presence Saint Mary's Hospital
🇺🇸
Kankakee, Illinois, United States
Illinois CancerCare-Kewanee Clinic
🇺🇸
Kewanee, Illinois, United States
Northwestern Medicine Lake Forest Hospital
🇺🇸
Lake Forest, Illinois, United States
AMG Libertyville - Oncology
🇺🇸
Libertyville, Illinois, United States
Illinois CancerCare-Macomb
🇺🇸
Macomb, Illinois, United States
Carle Physician Group-Mattoon/Charleston
🇺🇸
Mattoon, Illinois, United States
Loyola University Medical Center
🇺🇸
Maywood, Illinois, United States
Marjorie Weinberg Cancer Center at Loyola-Gottlieb
🇺🇸
Melrose Park, Illinois, United States
Trinity Medical Center
🇺🇸
Moline, Illinois, United States
Good Samaritan Regional Health Center
🇺🇸
Mount Vernon, Illinois, United States
Edward Hospital/Cancer Center
🇺🇸
Naperville, Illinois, United States
UC Comprehensive Cancer Center at Silver Cross
🇺🇸
New Lenox, Illinois, United States
Cancer Care Center of O'Fallon
🇺🇸
O'Fallon, Illinois, United States
University of Chicago Medicine-Orland Park
🇺🇸
Orland Park, Illinois, United States
Illinois CancerCare-Ottawa Clinic
🇺🇸
Ottawa, Illinois, United States
Radiation Oncology of Northern Illinois
🇺🇸
Ottawa, Illinois, United States
Illinois CancerCare-Pekin
🇺🇸
Pekin, Illinois, United States
OSF Saint Francis Radiation Oncology at Pekin
🇺🇸
Pekin, Illinois, United States
Illinois CancerCare-Peoria
🇺🇸
Peoria, Illinois, United States
OSF Saint Francis Radiation Oncology at Peoria Cancer Center
🇺🇸
Peoria, Illinois, United States
Methodist Medical Center of Illinois
🇺🇸
Peoria, Illinois, United States
OSF Saint Francis Medical Center
🇺🇸
Peoria, Illinois, United States
Illinois CancerCare-Peru
🇺🇸
Peru, Illinois, United States
Valley Radiation Oncology
🇺🇸
Peru, Illinois, United States
Edward Hospital/Cancer Center?Plainfield
🇺🇸
Plainfield, Illinois, United States
Illinois CancerCare-Princeton
🇺🇸
Princeton, Illinois, United States
Hematology Oncology Associates of Illinois - Skokie
🇺🇸
Skokie, Illinois, United States
North Shore Medical Center
🇺🇸
Skokie, Illinois, United States
Central Illinois Hematology Oncology Center
🇺🇸
Springfield, Illinois, United States
Southern Illinois University School of Medicine
🇺🇸
Springfield, Illinois, United States
Springfield Clinic
🇺🇸
Springfield, Illinois, United States
Springfield Memorial Hospital
🇺🇸
Springfield, Illinois, United States
Southwest Illinois Health Services LLP
🇺🇸
Swansea, Illinois, United States
Carle Cancer Center
🇺🇸
Urbana, Illinois, United States
The Carle Foundation Hospital
🇺🇸
Urbana, Illinois, United States
Northwestern Medicine Cancer Center Warrenville
🇺🇸
Warrenville, Illinois, United States
Illinois CancerCare - Washington
🇺🇸
Washington, Illinois, United States
Rush-Copley Healthcare Center
🇺🇸
Yorkville, Illinois, United States
Midwestern Regional Medical Center
🇺🇸
Zion, Illinois, United States
Michiana Hematology Oncology PC-Crown Point
🇺🇸
Crown Point, Indiana, United States
Michiana Hematology Oncology PC-Elkhart
🇺🇸
Elkhart, Indiana, United States
Deaconess Clinic Downtown
🇺🇸
Evansville, Indiana, United States
Indiana University/Melvin and Bren Simon Cancer Center
🇺🇸
Indianapolis, Indiana, United States
Sidney and Lois Eskenazi Hospital
🇺🇸
Indianapolis, Indiana, United States
Community Cancer Center East
🇺🇸
Indianapolis, Indiana, United States
Community Cancer Center South
🇺🇸
Indianapolis, Indiana, United States
Community Cancer Center North
🇺🇸
Indianapolis, Indiana, United States
Springmill Medical Center
🇺🇸
Indianapolis, Indiana, United States
Community Howard Regional Health
🇺🇸
Kokomo, Indiana, United States
IU Health Arnett Cancer Care
🇺🇸
Lafayette, Indiana, United States
Franciscan Saint Anthony Health-Michigan City
🇺🇸
Michigan City, Indiana, United States
Woodland Cancer Care Center
🇺🇸
Michigan City, Indiana, United States
Memorial Regional Cancer Center Day Road
🇺🇸
Mishawaka, Indiana, United States
Michiana Hematology Oncology PC-Mishawaka
🇺🇸
Mishawaka, Indiana, United States
Baptist Health Floyd
🇺🇸
New Albany, Indiana, United States
Chancellor Center for Oncology
🇺🇸
Newburgh, Indiana, United States
Michiana Hematology Oncology PC-Plymouth
🇺🇸
Plymouth, Indiana, United States
Reid Health
🇺🇸
Richmond, Indiana, United States
Memorial Hospital of South Bend
🇺🇸
South Bend, Indiana, United States
Michiana Hematology Oncology PC-Westville
🇺🇸
Westville, Indiana, United States
Mary Greeley Medical Center
🇺🇸
Ames, Iowa, United States
McFarland Clinic - Ames
🇺🇸
Ames, Iowa, United States
McFarland Clinic - Boone
🇺🇸
Boone, Iowa, United States
Saint Anthony Regional Hospital
🇺🇸
Carroll, Iowa, United States
Physicians' Clinic of Iowa PC
🇺🇸
Cedar Rapids, Iowa, United States
Mercy Hospital
🇺🇸
Coon Rapids, Minnesota, United States
Oncology Associates at Mercy Medical Center
🇺🇸
Cedar Rapids, Iowa, United States
Mercy Cancer Center-West Lakes
🇺🇸
Clive, Iowa, United States
Mission Cancer and Blood - West Des Moines
🇺🇸
Clive, Iowa, United States
Alegent Health Mercy Hospital
🇺🇸
Council Bluffs, Iowa, United States
Heartland Oncology and Hematology LLP
🇺🇸
Council Bluffs, Iowa, United States
Methodist Jennie Edmundson Hospital
🇺🇸
Council Bluffs, Iowa, United States
Greater Regional Medical Center
🇺🇸
Creston, Iowa, United States
Iowa Methodist Medical Center
🇺🇸
Des Moines, Iowa, United States
Mission Cancer and Blood - Des Moines
🇺🇸
Des Moines, Iowa, United States
Broadlawns Medical Center
🇺🇸
Des Moines, Iowa, United States
Mercy Medical Center - Des Moines
🇺🇸
Des Moines, Iowa, United States
Mission Cancer and Blood - Laurel
🇺🇸
Des Moines, Iowa, United States
Iowa Lutheran Hospital
🇺🇸
Des Moines, Iowa, United States
JCHC McCreery Cancer Center
🇺🇸
Fairfield, Iowa, United States
McFarland Clinic - Trinity Cancer Center
🇺🇸
Fort Dodge, Iowa, United States
Trinity Regional Medical Center
🇺🇸
Fort Dodge, Iowa, United States
McFarland Clinic - Jefferson
🇺🇸
Jefferson, Iowa, United States
McFarland Clinic - Marshalltown
🇺🇸
Marshalltown, Iowa, United States
Ottumwa Regional Health Center
🇺🇸
Ottumwa, Iowa, United States
Siouxland Regional Cancer Center
🇺🇸
Sioux City, Iowa, United States
Methodist West Hospital
🇺🇸
West Des Moines, Iowa, United States
Mercy Medical Center-West Lakes
🇺🇸
West Des Moines, Iowa, United States
Coffeyville Regional Medical Center
🇺🇸
Coffeyville, Kansas, United States
Newman Regional Health
🇺🇸
Emporia, Kansas, United States
University of Kansas Clinical Research Center
🇺🇸
Fairway, Kansas, United States
Central Care Cancer Center - Garden City
🇺🇸
Garden City, Kansas, United States
Saint Catherine Hospital
🇺🇸
Garden City, Kansas, United States
Central Care Cancer Center - Great Bend
🇺🇸
Great Bend, Kansas, United States
Saint Rose Ambulatory and Surgery Center
🇺🇸
Great Bend, Kansas, United States
HaysMed
🇺🇸
Hays, Kansas, United States
University of Kansas Cancer Center-West
🇺🇸
Kansas City, Kansas, United States
University of Kansas Cancer Center
🇺🇸
Kansas City, Kansas, United States
Lawrence Memorial Hospital
🇺🇸
Lawrence, Kansas, United States
Kansas Institute of Medicine Cancer and Blood Center
🇺🇸
Lenexa, Kansas, United States
Minimally Invasive Surgery Hospital
🇺🇸
Lenexa, Kansas, United States
The University of Kansas Cancer Center - Olathe
🇺🇸
Olathe, Kansas, United States
Menorah Medical Center
🇺🇸
Overland Park, Kansas, United States
University of Kansas Cancer Center-Overland Park
🇺🇸
Overland Park, Kansas, United States
Saint Luke's South Hospital
🇺🇸
Overland Park, Kansas, United States
Ascension Via Christi - Pittsburg
🇺🇸
Pittsburg, Kansas, United States
Salina Regional Health Center
🇺🇸
Salina, Kansas, United States
University of Kansas Health System Saint Francis Campus
🇺🇸
Topeka, Kansas, United States
University of Kansas Hospital-Westwood Cancer Center
🇺🇸
Westwood, Kansas, United States
Flaget Memorial Hospital
🇺🇸
Bardstown, Kentucky, United States
Baptist Health Corbin
🇺🇸
Corbin, Kentucky, United States
Commonwealth Cancer Center-Corbin
🇺🇸
Corbin, Kentucky, United States
Oncology Hematology Care Inc-Crestview
🇺🇸
Crestview Hills, Kentucky, United States
Saint Elizabeth Healthcare Edgewood
🇺🇸
Edgewood, Kentucky, United States
Baptist Health Hardin
🇺🇸
Elizabethtown, Kentucky, United States
Saint Elizabeth Healthcare Fort Thomas
🇺🇸
Fort Thomas, Kentucky, United States
Baptist Health Lexington
🇺🇸
Lexington, Kentucky, United States
Saint Joseph Radiation Oncology Resource Center
🇺🇸
Lexington, Kentucky, United States
Saint Joseph Hospital East
🇺🇸
Lexington, Kentucky, United States
University of Kentucky/Markey Cancer Center
🇺🇸
Lexington, Kentucky, United States
Saint Joseph London
🇺🇸
London, Kentucky, United States
Jewish Hospital
🇺🇸
Louisville, Kentucky, United States
The James Graham Brown Cancer Center at University of Louisville
🇺🇸
Louisville, Kentucky, United States
Baptist Health Louisville
🇺🇸
Louisville, Kentucky, United States
Saints Mary and Elizabeth Hospital
🇺🇸
Louisville, Kentucky, United States
UofL Health Medical Center Northeast
🇺🇸
Louisville, Kentucky, United States
Baptist Health Madisonville/Merle Mahr Cancer Center
🇺🇸
Madisonville, Kentucky, United States
Baptist Health Paducah
🇺🇸
Paducah, Kentucky, United States
Jewish Hospital Medical Center South
🇺🇸
Shepherdsville, Kentucky, United States
LSU Health Baton Rouge-North Clinic
🇺🇸
Baton Rouge, Louisiana, United States
Baton Rouge General Medical Center
🇺🇸
Baton Rouge, Louisiana, United States
Our Lady of the Lake Physician Group
🇺🇸
Baton Rouge, Louisiana, United States
Our Lady of The Lake
🇺🇸
Baton Rouge, Louisiana, United States
Hematology/Oncology Clinic PLLC
🇺🇸
Baton Rouge, Louisiana, United States
Louisiana Hematology Oncology Associates LLC
🇺🇸
Baton Rouge, Louisiana, United States
Mary Bird Perkins Cancer Center
🇺🇸
Baton Rouge, Louisiana, United States
Ochsner Health Center-Summa
🇺🇸
Baton Rouge, Louisiana, United States
The NeuroMedical Center-Clinic
🇺🇸
Baton Rouge, Louisiana, United States
Medical Center of Baton Rouge
🇺🇸
Baton Rouge, Louisiana, United States
Our Lady of the Lake Medical Oncology
🇺🇸
Baton Rouge, Louisiana, United States
Ochsner High Grove
🇺🇸
Baton Rouge, Louisiana, United States
Mary Bird Perkins Cancer Center - Covington
🇺🇸
Covington, Louisiana, United States
Northshore Oncology Associates-Covington
🇺🇸
Covington, Louisiana, United States
Ochsner Hematology Oncology North Shore - Covington (West Region)
🇺🇸
Covington, Louisiana, United States
Women's Cancer Care-Covington
🇺🇸
Covington, Louisiana, United States
Ochsner Medical Center West Bank
🇺🇸
Gretna, Louisiana, United States
Mary Bird Perkins Cancer Center - Houma
🇺🇸
Houma, Louisiana, United States
Oncology Center of The South Incorporated
🇺🇸
Houma, Louisiana, United States
Terrebonne General Medical Center
🇺🇸
Houma, Louisiana, United States
Ochsner Medical Center Kenner
🇺🇸
Kenner, Louisiana, United States
West Jefferson Medical Center
🇺🇸
Marrero, Louisiana, United States
East Jefferson General Hospital
🇺🇸
Metairie, Louisiana, United States
Robert Veith MD LLC
🇺🇸
Metairie, Louisiana, United States
Ochsner LSU Health Monroe Medical Center
🇺🇸
Monroe, Louisiana, United States
Louisiana State University Health Science Center
🇺🇸
New Orleans, Louisiana, United States
Tulane University School of Medicine
🇺🇸
New Orleans, Louisiana, United States
University Medical Center New Orleans
🇺🇸
New Orleans, Louisiana, United States
Ochsner Medical Center Jefferson
🇺🇸
New Orleans, Louisiana, United States
LSU Health Sciences Center at Shreveport
🇺🇸
Shreveport, Louisiana, United States
CHRISTUS Highland Medical Center
🇺🇸
Shreveport, Louisiana, United States
Harold Alfond Center for Cancer Care
🇺🇸
Augusta, Maine, United States
Eastern Maine Medical Center
🇺🇸
Bangor, Maine, United States
Waldo County General Hospital
🇺🇸
Belfast, Maine, United States
MaineHealth/SMHC Cancer Care and Blood Disorders-Biddeford
🇺🇸
Biddeford, Maine, United States
Lafayette Family Cancer Center-EMMC
🇺🇸
Brewer, Maine, United States
Maine Center for Cancer Medicine-Kennebunk
🇺🇸
Kennebunk, Maine, United States
Stephens Memorial Hospital
🇺🇸
Norway, Maine, United States
Penobscot Bay Medical Center
🇺🇸
Rockport, Maine, United States
MaineHealth/SMHC Cancer Care and Blood Disorders-Sanford
🇺🇸
Sanford, Maine, United States
Maine Center for Cancer Medicine-Scarborough
🇺🇸
Scarborough, Maine, United States
Maine Medical Center- Scarborough Campus
🇺🇸
Scarborough, Maine, United States
Maine Medical Partners - South Portland
🇺🇸
South Portland, Maine, United States
Maine Center for Cancer Medicine-Topsham
🇺🇸
Topsham, Maine, United States
Luminis Health Anne Arundel Medical Center
🇺🇸
Annapolis, Maryland, United States
University of Maryland/Greenebaum Cancer Center
🇺🇸
Baltimore, Maryland, United States
Greater Baltimore Medical Center
🇺🇸
Baltimore, Maryland, United States
Sinai Hospital of Baltimore
🇺🇸
Baltimore, Maryland, United States
MedStar Union Memorial Hospital
🇺🇸
Baltimore, Maryland, United States
MedStar Franklin Square Medical Center/Weinberg Cancer Institute
🇺🇸
Baltimore, Maryland, United States
MedStar Good Samaritan Hospital
🇺🇸
Baltimore, Maryland, United States
Johns Hopkins University/Sidney Kimmel Cancer Center
🇺🇸
Baltimore, Maryland, United States
Walter Reed National Military Medical Center
🇺🇸
Bethesda, Maryland, United States
National Institutes of Health Clinical Center
🇺🇸
Bethesda, Maryland, United States
UPMC Western Maryland
🇺🇸
Cumberland, Maryland, United States
University of Maryland Shore Medical Center at Easton
🇺🇸
Easton, Maryland, United States
Christiana Care - Union Hospital
🇺🇸
Elkton, Maryland, United States
Frederick Memorial Hospital
🇺🇸
Frederick, Maryland, United States
FMH James M Stockman Cancer Institute
🇺🇸
Frederick, Maryland, United States
MedStar Montgomery Medical Center
🇺🇸
Olney, Maryland, United States
Northwest Hospital Center
🇺🇸
Randallstown, Maryland, United States
TidalHealth Peninsula Regional
🇺🇸
Salisbury, Maryland, United States
William E Kahlert Regional Cancer Center/Sinai Hospital
🇺🇸
Westminster, Maryland, United States
Beverly Hospital
🇺🇸
Beverly, Massachusetts, United States
Tufts Medical Center
🇺🇸
Boston, Massachusetts, United States
Massachusetts General Hospital Cancer Center
🇺🇸
Boston, Massachusetts, United States
Boston Medical Center
🇺🇸
Boston, Massachusetts, United States
Beth Israel Deaconess Medical Center
🇺🇸
Boston, Massachusetts, United States
Dana-Farber Cancer Institute
🇺🇸
Boston, Massachusetts, United States
Lahey Hospital and Medical Center
🇺🇸
Burlington, Massachusetts, United States
Simonds-Sinon Regional Cancer Center
🇺🇸
Fitchburg, Massachusetts, United States
MetroWest Medical Center-Framingham Union Hospital
🇺🇸
Framingham, Massachusetts, United States
Addison Gilbert Hospital
🇺🇸
Gloucester, Massachusetts, United States
Lowell General Hospital
🇺🇸
Lowell, Massachusetts, United States
Lahey Medical Center-Peabody
🇺🇸
Peabody, Massachusetts, United States
Baystate Medical Center
🇺🇸
Springfield, Massachusetts, United States
Winchester Hospital
🇺🇸
Winchester, Massachusetts, United States
UMass Memorial Medical Center - University Campus
🇺🇸
Worcester, Massachusetts, United States
Hickman Cancer Center
🇺🇸
Adrian, Michigan, United States
Trinity Health Saint Joseph Mercy Hospital Ann Arbor
🇺🇸
Ann Arbor, Michigan, United States
C S Mott Children's Hospital
🇺🇸
Ann Arbor, Michigan, United States
University of Michigan Comprehensive Cancer Center
🇺🇸
Ann Arbor, Michigan, United States
Bronson Battle Creek
🇺🇸
Battle Creek, Michigan, United States
Trinity Health IHA Medical Group Hematology Oncology - Brighton
🇺🇸
Brighton, Michigan, United States
Trinity Health Medical Center - Brighton
🇺🇸
Brighton, Michigan, United States
Henry Ford Cancer Institute-Downriver
🇺🇸
Brownstown, Michigan, United States
Trinity Health IHA Medical Group Hematology Oncology - Canton
🇺🇸
Canton, Michigan, United States
Trinity Health Medical Center - Canton
🇺🇸
Canton, Michigan, United States
Caro Cancer Center
🇺🇸
Caro, Michigan, United States
Chelsea Hospital
🇺🇸
Chelsea, Michigan, United States
Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital
🇺🇸
Chelsea, Michigan, United States
Hematology Oncology Consultants-Clarkston
🇺🇸
Clarkston, Michigan, United States
Newland Medical Associates-Clarkston
🇺🇸
Clarkston, Michigan, United States
Henry Ford Hematology Oncology - Hayes
🇺🇸
Clinton Township, Michigan, United States
Henry Ford Macomb Hospital-Clinton Township
🇺🇸
Clinton Township, Michigan, United States
Corewell Health Dearborn Hospital
🇺🇸
Dearborn, Michigan, United States
Henry Ford Medical Center-Fairlane
🇺🇸
Dearborn, Michigan, United States
Wayne State University/Karmanos Cancer Institute
🇺🇸
Detroit, Michigan, United States
Henry Ford Hospital
🇺🇸
Detroit, Michigan, United States
Henry Ford Health Saint John Hospital
🇺🇸
Detroit, Michigan, United States
Henry Ford River District Hospital
🇺🇸
East China Township, Michigan, United States
Michigan State University Clinical Center
🇺🇸
East Lansing, Michigan, United States
OSF Saint Francis Hospital and Medical Group
🇺🇸
Escanaba, Michigan, United States
Corewell Health Farmington Hills Hospital
🇺🇸
Farmington Hills, Michigan, United States
Cancer Hematology Centers - Flint
🇺🇸
Flint, Michigan, United States
Genesee Hematology Oncology PC
🇺🇸
Flint, Michigan, United States
Genesys Hurley Cancer Institute
🇺🇸
Flint, Michigan, United States
Hurley Medical Center
🇺🇸
Flint, Michigan, United States
Corewell Health Grand Rapids Hospitals - Butterworth Hospital
🇺🇸
Grand Rapids, Michigan, United States
Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital
🇺🇸
Grand Rapids, Michigan, United States
Trinity Health Grand Rapids Hospital
🇺🇸
Grand Rapids, Michigan, United States
Henry Ford Saint John Hospital - Academic
🇺🇸
Grosse Pointe Woods, Michigan, United States
Henry Ford Saint John Hospital - Breast
🇺🇸
Grosse Pointe Woods, Michigan, United States
Henry Ford Saint John Hospital - Van Elslander
🇺🇸
Grosse Pointe Woods, Michigan, United States
William Beaumont Hospital-Grosse Pointe
🇺🇸
Grosse Pointe, Michigan, United States
Allegiance Health
🇺🇸
Jackson, Michigan, United States
Bronson Methodist Hospital
🇺🇸
Kalamazoo, Michigan, United States
West Michigan Cancer Center
🇺🇸
Kalamazoo, Michigan, United States
Ascension Borgess Hospital
🇺🇸
Kalamazoo, Michigan, United States
Karmanos Cancer Institute at McLaren Greater Lansing
🇺🇸
Lansing, Michigan, United States
University of Michigan Health - Sparrow Lansing
🇺🇸
Lansing, Michigan, United States
Hope Cancer Clinic
🇺🇸
Livonia, Michigan, United States
Trinity Health Saint Mary Mercy Livonia Hospital
🇺🇸
Livonia, Michigan, United States
Henry Ford Saint John Hospital - Macomb Medical
🇺🇸
Macomb, Michigan, United States
Henry Ford Warren Hospital - Breast Macomb
🇺🇸
Macomb, Michigan, United States
Saint Mary's Oncology/Hematology Associates of Marlette
🇺🇸
Marlette, Michigan, United States
MyMichigan Medical Center Midland
🇺🇸
Midland, Michigan, United States
Monroe Cancer Center
🇺🇸
Monroe, Michigan, United States
Toledo Clinic Cancer Centers-Monroe
🇺🇸
Monroe, Michigan, United States
Trinity Health Muskegon Hospital
🇺🇸
Muskegon, Michigan, United States
Corewell Health Lakeland Hospitals - Niles Hospital
🇺🇸
Niles, Michigan, United States
Cancer and Hematology Centers of Western Michigan - Norton Shores
🇺🇸
Norton Shores, Michigan, United States
Henry Ford Health Providence Novi Hospital
🇺🇸
Novi, Michigan, United States
Henry Ford Medical Center-Columbus
🇺🇸
Novi, Michigan, United States
Hope Cancer Center
🇺🇸
Pontiac, Michigan, United States
Michigan Healthcare Professionals Pontiac
🇺🇸
Pontiac, Michigan, United States
Newland Medical Associates-Pontiac
🇺🇸
Pontiac, Michigan, United States
Trinity Health Saint Joseph Mercy Oakland Hospital
🇺🇸
Pontiac, Michigan, United States
Huron Medical Center PC
🇺🇸
Port Huron, Michigan, United States
Lake Huron Medical Center
🇺🇸
Port Huron, Michigan, United States
Corewell Health Reed City Hospital
🇺🇸
Reed City, Michigan, United States
Henry Ford Rochester Hospital
🇺🇸
Rochester Hills, Michigan, United States
Michigan Cancer Specialists
🇺🇸
Roseville, Michigan, United States
Oakland Colon Rectal Associates
🇺🇸
Royal Oak, Michigan, United States
Cancer Care Associates PC
🇺🇸
Royal Oak, Michigan, United States
Comprehensive Medical Center PLLC
🇺🇸
Royal Oak, Michigan, United States
Corewell Health Children's
🇺🇸
Royal Oak, Michigan, United States
Corewell Health William Beaumont University Hospital
🇺🇸
Royal Oak, Michigan, United States
Hematology Oncology Consultants PC-Royal Oak
🇺🇸
Royal Oak, Michigan, United States
Oakland Medical Group
🇺🇸
Royal Oak, Michigan, United States
MyMichigan Medical Center Saginaw
🇺🇸
Saginaw, Michigan, United States
Oncology Hematology Associates of Saginaw Valley PC
🇺🇸
Saginaw, Michigan, United States
Corewell Health Lakeland Hospitals - Marie Yeager Cancer Center
🇺🇸
Saint Joseph, Michigan, United States
Corewell Health Lakeland Hospitals - Saint Joseph Hospital
🇺🇸
Saint Joseph, Michigan, United States
Henry Ford Macomb Health Center - Shelby Township
🇺🇸
Shelby, Michigan, United States
Henry Ford Health Providence Southfield Hospital
🇺🇸
Southfield, Michigan, United States
Bhadresh Nayak MD PC-Sterling Heights
🇺🇸
Sterling Heights, Michigan, United States
Premier Hematology Oncology Care
🇺🇸
Sterling Heights, Michigan, United States
Mitchell Folbe MD PC
🇺🇸
Sterling Heights, Michigan, United States
MyMichigan Medical Center Tawas
🇺🇸
Tawas City, Michigan, United States
Munson Medical Center
🇺🇸
Traverse City, Michigan, United States
Michigan Institute of Urology-Town Center
🇺🇸
Troy, Michigan, United States
Claudia BR Herke MD PC
🇺🇸
Troy, Michigan, United States
Corewell Health Beaumont Troy Hospital
🇺🇸
Troy, Michigan, United States
Hematology Oncology Consultants PC-Troy
🇺🇸
Troy, Michigan, United States
Advanced Breast Care Center PLLC
🇺🇸
Warren, Michigan, United States
Henry Ford Health Warren Hospital
🇺🇸
Warren, Michigan, United States
Henry Ford Madison Heights Hospital - Breast
🇺🇸
Warren, Michigan, United States
Henry Ford Warren Hospital - GLCMS
🇺🇸
Warren, Michigan, United States
Macomb Hematology Oncology PC
🇺🇸
Warren, Michigan, United States
Henry Ford West Bloomfield Hospital
🇺🇸
West Bloomfield, Michigan, United States
Saint Mary's Oncology/Hematology Associates of West Branch
🇺🇸
West Branch, Michigan, United States
Henry Ford Wyandotte Hospital
🇺🇸
Wyandotte, Michigan, United States
University of Michigan Health - West
🇺🇸
Wyoming, Michigan, United States
Huron Gastroenterology PC
🇺🇸
Ypsilanti, Michigan, United States
Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus
🇺🇸
Ypsilanti, Michigan, United States
Riverwood Healthcare Center
🇺🇸
Aitkin, Minnesota, United States
Essentia Health - Baxter Clinic
🇺🇸
Baxter, Minnesota, United States
Sanford Joe Lueken Cancer Center
🇺🇸
Bemidji, Minnesota, United States
Essentia Health Saint Joseph's Medical Center
🇺🇸
Brainerd, Minnesota, United States
Fairview Ridges Hospital
🇺🇸
Burnsville, Minnesota, United States
Minnesota Oncology - Burnsville
🇺🇸
Burnsville, Minnesota, United States
Cambridge Medical Center
🇺🇸
Cambridge, Minnesota, United States
Essentia Health - Deer River Clinic
🇺🇸
Deer River, Minnesota, United States
Essentia Health Saint Mary's - Detroit Lakes Clinic
🇺🇸
Detroit Lakes, Minnesota, United States
Essentia Health Cancer Center
🇺🇸
Duluth, Minnesota, United States
Essentia Health Saint Mary's Medical Center
🇺🇸
Duluth, Minnesota, United States
Miller-Dwan Hospital
🇺🇸
Duluth, Minnesota, United States
Fairview Southdale Hospital
🇺🇸
Edina, Minnesota, United States
Essentia Health - Ely Clinic
🇺🇸
Ely, Minnesota, United States
Lake Region Healthcare Corporation-Cancer Care
🇺🇸
Fergus Falls, Minnesota, United States
Essentia Health - Fosston
🇺🇸
Fosston, Minnesota, United States
Unity Hospital
🇺🇸
Fridley, Minnesota, United States
Essentia Health Hibbing Clinic
🇺🇸
Hibbing, Minnesota, United States
Essentia Health - International Falls Clinic
🇺🇸
International Falls, Minnesota, United States
Fairview Clinics and Surgery Center Maple Grove
🇺🇸
Maple Grove, Minnesota, United States
Minnesota Oncology Hematology PA-Maplewood
🇺🇸
Maplewood, Minnesota, United States
Saint John's Hospital - Healtheast
🇺🇸
Maplewood, Minnesota, United States
Abbott-Northwestern Hospital
🇺🇸
Minneapolis, Minnesota, United States
Hennepin County Medical Center
🇺🇸
Minneapolis, Minnesota, United States
Health Partners Inc
🇺🇸
Minneapolis, Minnesota, United States
University of Minnesota/Masonic Cancer Center
🇺🇸
Minneapolis, Minnesota, United States
Monticello Cancer Center
🇺🇸
Monticello, Minnesota, United States
Essentia Health - Moose Lake Clinic
🇺🇸
Moose Lake, Minnesota, United States
New Ulm Medical Center
🇺🇸
New Ulm, Minnesota, United States
Essentia Health - Park Rapids
🇺🇸
Park Rapids, Minnesota, United States
Fairview Northland Medical Center
🇺🇸
Princeton, Minnesota, United States
North Memorial Medical Health Center
🇺🇸
Robbinsdale, Minnesota, United States
Mayo Clinic in Rochester
🇺🇸
Rochester, Minnesota, United States
Park Nicollet Clinic - Saint Louis Park
🇺🇸
Saint Louis Park, Minnesota, United States
Regions Hospital
🇺🇸
Saint Paul, Minnesota, United States
United Hospital
🇺🇸
Saint Paul, Minnesota, United States
Essentia Health Sandstone
🇺🇸
Sandstone, Minnesota, United States
Saint Francis Regional Medical Center
🇺🇸
Shakopee, Minnesota, United States
Lakeview Hospital
🇺🇸
Stillwater, Minnesota, United States
Essentia Health Virginia Clinic
🇺🇸
Virginia, Minnesota, United States
Ridgeview Medical Center
🇺🇸
Waconia, Minnesota, United States
Rice Memorial Hospital
🇺🇸
Willmar, Minnesota, United States
Minnesota Oncology Hematology PA-Woodbury
🇺🇸
Woodbury, Minnesota, United States
Sanford Cancer Center Worthington
🇺🇸
Worthington, Minnesota, United States
Fairview Lakes Medical Center
🇺🇸
Wyoming, Minnesota, United States
Baptist Memorial Hospital and Cancer Center-Golden Triangle
🇺🇸
Columbus, Mississippi, United States
Baptist Cancer Center-Grenada
🇺🇸
Grenada, Mississippi, United States
Hattiesburg Clinic - Hematology/Oncology Clinic
🇺🇸
Hattiesburg, Mississippi, United States
Forrest General Hospital / Cancer Center
🇺🇸
Hattiesburg, Mississippi, United States
University of Mississippi Medical Center
🇺🇸
Jackson, Mississippi, United States
Baptist Memorial Hospital and Cancer Center-Union County
🇺🇸
New Albany, Mississippi, United States
Baptist Memorial Hospital and Cancer Center-Oxford
🇺🇸
Oxford, Mississippi, United States
Singing River Hospital
🇺🇸
Pascagoula, Mississippi, United States
Baptist Memorial Hospital and Cancer Center-Desoto
🇺🇸
Southhaven, Mississippi, United States
Central Care Cancer Center - Bolivar
🇺🇸
Bolivar, Missouri, United States
Parkland Health Center-Bonne Terre
🇺🇸
Bonne Terre, Missouri, United States
Cox Cancer Center Branson
🇺🇸
Branson, Missouri, United States
Saint Francis Medical Center
🇺🇸
Cape Girardeau, Missouri, United States
Southeast Cancer Center
🇺🇸
Cape Girardeau, Missouri, United States
Saint Luke's Hospital
🇺🇸
Chesterfield, Missouri, United States
MU Health - University Hospital/Ellis Fischel Cancer Center
🇺🇸
Columbia, Missouri, United States
Siteman Cancer Center at West County Hospital
🇺🇸
Creve Coeur, Missouri, United States
Parkland Health Center - Farmington
🇺🇸
Farmington, Missouri, United States
Centerpoint Medical Center LLC
🇺🇸
Independence, Missouri, United States
MU Health Care Goldschmidt Cancer Center
🇺🇸
Jefferson City, Missouri, United States
Freeman Health System
🇺🇸
Joplin, Missouri, United States
Mercy Hospital Joplin
🇺🇸
Joplin, Missouri, United States
University Health Truman Medical Center
🇺🇸
Kansas City, Missouri, United States
Saint Luke's Hospital of Kansas City
🇺🇸
Kansas City, Missouri, United States
The University of Kansas Cancer Center-South
🇺🇸
Kansas City, Missouri, United States
Research Medical Center
🇺🇸
Kansas City, Missouri, United States
University of Kansas Cancer Center - North
🇺🇸
Kansas City, Missouri, United States
University of Kansas Cancer Center - Lee's Summit
🇺🇸
Lee's Summit, Missouri, United States
Saint Luke's East - Lee's Summit
🇺🇸
Lee's Summit, Missouri, United States
Liberty Radiation Oncology Center
🇺🇸
Liberty, Missouri, United States
University of Kansas Cancer Center at North Kansas City Hospital
🇺🇸
North Kansas City, Missouri, United States
Delbert Day Cancer Institute at PCRMC
🇺🇸
Rolla, Missouri, United States
Mercy Clinic-Rolla-Cancer and Hematology
🇺🇸
Rolla, Missouri, United States
Heartland Regional Medical Center
🇺🇸
Saint Joseph, Missouri, United States
Saint Louis Cancer and Breast Institute-South City
🇺🇸
Saint Louis, Missouri, United States
Washington University School of Medicine
🇺🇸
Saint Louis, Missouri, United States
Mercy Hospital South
🇺🇸
Saint Louis, Missouri, United States
Siteman Cancer Center-South County
🇺🇸
Saint Louis, Missouri, United States
Missouri Baptist Medical Center
🇺🇸
Saint Louis, Missouri, United States
Siteman Cancer Center at Christian Hospital
🇺🇸
Saint Louis, Missouri, United States
Mercy Hospital Saint Louis
🇺🇸
Saint Louis, Missouri, United States
Siteman Cancer Center at Saint Peters Hospital
🇺🇸
Saint Peters, Missouri, United States
Sainte Genevieve County Memorial Hospital
🇺🇸
Sainte Genevieve, Missouri, United States
Mercy Hospital Springfield
🇺🇸
Springfield, Missouri, United States
CoxHealth South Hospital
🇺🇸
Springfield, Missouri, United States
Missouri Baptist Sullivan Hospital
🇺🇸
Sullivan, Missouri, United States
BJC Outpatient Center at Sunset Hills
🇺🇸
Sunset Hills, Missouri, United States
Community Hospital of Anaconda
🇺🇸
Anaconda, Montana, United States
Billings Clinic Cancer Center
🇺🇸
Billings, Montana, United States
Saint Vincent Healthcare
🇺🇸
Billings, Montana, United States
Saint Vincent Frontier Cancer Center
🇺🇸
Billings, Montana, United States
Bozeman Health Deaconess Hospital
🇺🇸
Bozeman, Montana, United States
Saint James Community Hospital and Cancer Treatment Center
🇺🇸
Butte, Montana, United States
Benefis Sletten Cancer Institute
🇺🇸
Great Falls, Montana, United States
Saint Peter's Community Hospital
🇺🇸
Helena, Montana, United States
Logan Health Medical Center
🇺🇸
Kalispell, Montana, United States
Saint Patrick Hospital - Community Hospital
🇺🇸
Missoula, Montana, United States
Community Medical Center
🇺🇸
Scranton, Pennsylvania, United States
Nebraska Medicine-Bellevue
🇺🇸
Bellevue, Nebraska, United States
Nebraska Cancer Specialists/Oncology Hematology West PC
🇺🇸
Grand Island, Nebraska, United States
Nebraska Medicine Heartland Hematology Oncology
🇺🇸
Kearney, Nebraska, United States
CHI Health Good Samaritan
🇺🇸
Kearney, Nebraska, United States
Nebraska Hematology and Oncology
🇺🇸
Lincoln, Nebraska, United States
Nebraska Cancer Research Center
🇺🇸
Lincoln, Nebraska, United States
Saint Elizabeth Regional Medical Center
🇺🇸
Lincoln, Nebraska, United States
Cancer Partners of Nebraska
🇺🇸
Lincoln, Nebraska, United States
Faith Regional Health Services Carson Cancer Center
🇺🇸
Norfolk, Nebraska, United States
Great Plains Health Callahan Cancer Center
🇺🇸
North Platte, Nebraska, United States
Nebraska Cancer Specialists/Oncology Hematology West PC - MECC
🇺🇸
Omaha, Nebraska, United States
Nebraska Methodist Hospital
🇺🇸
Omaha, Nebraska, United States
Oncology Associates PC
🇺🇸
Omaha, Nebraska, United States
Nebraska Medicine-Village Pointe
🇺🇸
Omaha, Nebraska, United States
Alegent Health Immanuel Medical Center
🇺🇸
Omaha, Nebraska, United States
Hematology and Oncology Consultants PC
🇺🇸
Omaha, Nebraska, United States
Alegent Health Bergan Mercy Medical Center
🇺🇸
Omaha, Nebraska, United States
Nebraska Cancer Specialists - Omaha
🇺🇸
Omaha, Nebraska, United States
Alegent Health Lakeside Hospital
🇺🇸
Omaha, Nebraska, United States
Oncology Hematology West PC
🇺🇸
Omaha, Nebraska, United States
Creighton University Medical Center
🇺🇸
Omaha, Nebraska, United States
University of Nebraska Medical Center
🇺🇸
Omaha, Nebraska, United States
Midlands Community Hospital
🇺🇸
Papillion, Nebraska, United States
Regional West Medical Center Cancer Center
🇺🇸
Scottsbluff, Nebraska, United States
Carson Tahoe Regional Medical Center
🇺🇸
Carson City, Nevada, United States
Cancer and Blood Specialists-Henderson
🇺🇸
Henderson, Nevada, United States
Comprehensive Cancer Centers of Nevada - Henderson
🇺🇸
Henderson, Nevada, United States
Comprehensive Cancer Centers of Nevada-Horizon Ridge
🇺🇸
Henderson, Nevada, United States
Las Vegas Cancer Center-Henderson
🇺🇸
Henderson, Nevada, United States
OptumCare Cancer Care at Seven Hills
🇺🇸
Henderson, Nevada, United States
Comprehensive Cancer Centers of Nevada-Southeast Henderson
🇺🇸
Henderson, Nevada, United States
GenesisCare USA - Henderson
🇺🇸
Henderson, Nevada, United States
Las Vegas Urology - Green Valley
🇺🇸
Henderson, Nevada, United States
Las Vegas Urology - Pebble
🇺🇸
Henderson, Nevada, United States
Urology Specialists of Nevada - Green Valley
🇺🇸
Henderson, Nevada, United States
Las Vegas Urology - Pecos
🇺🇸
Las Vegas, Nevada, United States
Desert West Surgery
🇺🇸
Las Vegas, Nevada, United States
OptumCare Cancer Care at Charleston
🇺🇸
Las Vegas, Nevada, United States
University Medical Center of Southern Nevada
🇺🇸
Las Vegas, Nevada, United States
Cancer and Blood Specialists-Shadow
🇺🇸
Las Vegas, Nevada, United States
Radiation Oncology Centers of Nevada Central
🇺🇸
Las Vegas, Nevada, United States
Urology Specialists of Nevada - Central
🇺🇸
Las Vegas, Nevada, United States
GenesisCare USA - Las Vegas
🇺🇸
Las Vegas, Nevada, United States
HealthCare Partners Medical Group Oncology/Hematology-Maryland Parkway
🇺🇸
Las Vegas, Nevada, United States
Sunrise Hospital and Medical Center
🇺🇸
Las Vegas, Nevada, United States
HealthCare Partners Medical Group Oncology/Hematology-San Martin
🇺🇸
Las Vegas, Nevada, United States
Las Vegas Prostate Cancer Center
🇺🇸
Las Vegas, Nevada, United States
Las Vegas Urology - Sunset
🇺🇸
Las Vegas, Nevada, United States
Urology Specialists of Nevada - Southwest
🇺🇸
Las Vegas, Nevada, United States
Radiation Oncology Centers of Nevada Southeast
🇺🇸
Las Vegas, Nevada, United States
Cancer Therapy and Integrative Medicine
🇺🇸
Las Vegas, Nevada, United States
Ann M Wierman MD LTD
🇺🇸
Las Vegas, Nevada, United States
Cancer and Blood Specialists-Tenaya
🇺🇸
Las Vegas, Nevada, United States
Comprehensive Cancer Centers of Nevada - Northwest
🇺🇸
Las Vegas, Nevada, United States
GenesisCare USA - Vegas Tenaya
🇺🇸
Las Vegas, Nevada, United States
HealthCare Partners Medical Group Oncology/Hematology-Tenaya
🇺🇸
Las Vegas, Nevada, United States
Las Vegas Urology - Cathedral Rock
🇺🇸
Las Vegas, Nevada, United States
Las Vegas Urology - Smoke Ranch
🇺🇸
Las Vegas, Nevada, United States
OptumCare Cancer Care at MountainView
🇺🇸
Las Vegas, Nevada, United States
Urology Specialists of Nevada - Northwest
🇺🇸
Las Vegas, Nevada, United States
Alliance for Childhood Diseases/Cure 4 the Kids Foundation
🇺🇸
Las Vegas, Nevada, United States
Comprehensive Cancer Centers of Nevada - Town Center
🇺🇸
Las Vegas, Nevada, United States
Comprehensive Cancer Centers of Nevada-Summerlin
🇺🇸
Las Vegas, Nevada, United States
Summerlin Hospital Medical Center
🇺🇸
Las Vegas, Nevada, United States
Las Vegas Cancer Center-Medical Center
🇺🇸
Las Vegas, Nevada, United States
Comprehensive Cancer Centers of Nevada
🇺🇸
Las Vegas, Nevada, United States
GenesisCare USA - Fort Apache
🇺🇸
Las Vegas, Nevada, United States
OptumCare Cancer Care at Fort Apache
🇺🇸
Las Vegas, Nevada, United States
HealthCare Partners Medical Group Oncology/Hematology-Centennial Hills
🇺🇸
Las Vegas, Nevada, United States
Comprehensive Cancer Centers of Nevada - Central Valley
🇺🇸
Las Vegas, Nevada, United States
Hope Cancer Care of Nevada-Pahrump
🇺🇸
Pahrump, Nevada, United States
Center of Hope at Renown Medical Center
🇺🇸
Reno, Nevada, United States
Renown Regional Medical Center
🇺🇸
Reno, Nevada, United States
Saint Mary's Regional Medical Center
🇺🇸
Reno, Nevada, United States
Radiation Oncology Associates
🇺🇸
Reno, Nevada, United States
New Hampshire Oncology Hematology PA-Concord
🇺🇸
Concord, New Hampshire, United States
Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center
🇺🇸
Lebanon, New Hampshire, United States
Dartmouth Cancer Center - Manchester
🇺🇸
Manchester, New Hampshire, United States
Elliot Hospital
🇺🇸
Manchester, New Hampshire, United States
Solinsky Center for Cancer Care
🇺🇸
Manchester, New Hampshire, United States
Dartmouth Cancer Center - Nashua
🇺🇸
Nashua, New Hampshire, United States
Ocean University Medical Center
🇺🇸
Brick, New Jersey, United States
AtlantiCare Health Park-Cape May Court House
🇺🇸
Cape May Court House, New Jersey, United States
AtlantiCare Surgery Center
🇺🇸
Egg Harbor Township, New Jersey, United States
Trinitas Hospital and Comprehensive Cancer Center - Williamson Street Campus
🇺🇸
Elizabeth, New Jersey, United States
Hunterdon Medical Center
🇺🇸
Flemington, New Jersey, United States
Hackensack University Medical Center
🇺🇸
Hackensack, New Jersey, United States
Bayshore Community Hospital
🇺🇸
Holmdel, New Jersey, United States
Monmouth Medical Center Southern Campus
🇺🇸
Lakewood, New Jersey, United States
Saint Barnabas Medical Center
🇺🇸
Livingston, New Jersey, United States
Monmouth Medical Center
🇺🇸
Long Branch, New Jersey, United States
Southern Ocean County Medical Center
🇺🇸
Manahawkin, New Jersey, United States
Memorial Sloan Kettering Monmouth
🇺🇸
Middletown, New Jersey, United States
Morristown Medical Center
🇺🇸
Morristown, New Jersey, United States
Inspira Medical Center Mullica Hill
🇺🇸
Mullica Hill, New Jersey, United States
Jersey Shore Medical Center
🇺🇸
Neptune, New Jersey, United States
Rutgers Cancer Institute of New Jersey
🇺🇸
New Brunswick, New Jersey, United States
Newark Beth Israel Medical Center
🇺🇸
Newark, New Jersey, United States
Capital Health Medical Center-Hopewell
🇺🇸
Pennington, New Jersey, United States
Riverview Medical Center/Booker Cancer Center
🇺🇸
Red Bank, New Jersey, United States
Sidney Kimmel Cancer Center Washington Township
🇺🇸
Sewell, New Jersey, United States
Overlook Hospital
🇺🇸
Summit, New Jersey, United States
Inspira Medical Center Vineland
🇺🇸
Vineland, New Jersey, United States
Lovelace Medical Center-Downtown
🇺🇸
Albuquerque, New Mexico, United States
Southwest Gynecologic Oncology Associates Inc
🇺🇸
Albuquerque, New Mexico, United States
University of New Mexico Cancer Center
🇺🇸
Albuquerque, New Mexico, United States
New Mexico Oncology Hematology Consultants
🇺🇸
Albuquerque, New Mexico, United States
Presbyterian Kaseman Hospital
🇺🇸
Albuquerque, New Mexico, United States
Memorial Medical Center - Las Cruces
🇺🇸
Las Cruces, New Mexico, United States
Presbyterian Rust Medical Center/Jorgensen Cancer Center
🇺🇸
Rio Rancho, New Mexico, United States
Christus Saint Vincent Regional Cancer Center
🇺🇸
Santa Fe, New Mexico, United States
South Shore University Hospital
🇺🇸
Bay Shore, New York, United States
Montefiore Medical Center-Einstein Campus
🇺🇸
Bronx, New York, United States
Montefiore Medical Center-Weiler Hospital
🇺🇸
Bronx, New York, United States
Children's Hospital at Montefiore
🇺🇸
Bronx, New York, United States
Montefiore Medical Center - Moses Campus
🇺🇸
Bronx, New York, United States
State University of New York Downstate Medical Center
🇺🇸
Brooklyn, New York, United States
Roswell Park Cancer Institute
🇺🇸
Buffalo, New York, United States
Arnot Ogden Medical Center/Falck Cancer Center
🇺🇸
Elmira, New York, United States
Glens Falls Hospital
🇺🇸
Glens Falls, New York, United States
Memorial Sloan Kettering Westchester
🇺🇸
Harrison, New York, United States
Northwell Health/Center for Advanced Medicine
🇺🇸
Lake Success, New York, United States
North Shore University Hospital
🇺🇸
Manhasset, New York, United States
Long Island Jewish Medical Center
🇺🇸
New Hyde Park, New York, United States
Mount Sinai Hospital
🇺🇸
New York, New York, United States
NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
🇺🇸
New York, New York, United States
Manhattan Eye Ear and Throat Hospital
🇺🇸
New York, New York, United States
Memorial Sloan Kettering Cancer Center
🇺🇸
New York, New York, United States
NYP/Weill Cornell Medical Center
🇺🇸
New York, New York, United States
Lenox Hill Hospital
🇺🇸
New York, New York, United States
Rochester General Hospital
🇺🇸
Rochester, New York, United States
University of Rochester
🇺🇸
Rochester, New York, United States
Stony Brook University Medical Center
🇺🇸
Stony Brook, New York, United States
State University of New York Upstate Medical University
🇺🇸
Syracuse, New York, United States
SUNY Upstate Medical Center-Community Campus
🇺🇸
Syracuse, New York, United States
Dickstein Cancer Treatment Center
🇺🇸
White Plains, New York, United States
Mission Hospital
🇺🇸
Asheville, North Carolina, United States
AdventHealth Infusion Center Asheville
🇺🇸
Asheville, North Carolina, United States
Messino Cancer Centers
🇺🇸
Asheville, North Carolina, United States
Hope Women's Cancer Centers-Asheville
🇺🇸
Asheville, North Carolina, United States
Waverly Hematology Oncology
🇺🇸
Cary, North Carolina, United States
UNC Lineberger Comprehensive Cancer Center
🇺🇸
Chapel Hill, North Carolina, United States
Novant Health Presbyterian Medical Center
🇺🇸
Charlotte, North Carolina, United States
Novant Health Carolina Surgical - Randolph
🇺🇸
Charlotte, North Carolina, United States
Oncology Specialists of Charlotte
🇺🇸
Charlotte, North Carolina, United States
Southern Oncology Specialists-Charlotte
🇺🇸
Charlotte, North Carolina, United States
Southeastern Medical Oncology Center-Clinton
🇺🇸
Clinton, North Carolina, United States
AdventHealth Infusion Center Haywood
🇺🇸
Clyde, North Carolina, United States
Durham VA Medical Center
🇺🇸
Durham, North Carolina, United States
Duke University Medical Center
🇺🇸
Durham, North Carolina, United States
Southeastern Medical Oncology Center-Goldsboro
🇺🇸
Goldsboro, North Carolina, United States
Wayne Memorial Hospital
🇺🇸
Goldsboro, North Carolina, United States
Novant Health Breast Surgery - Greensboro
🇺🇸
Greensboro, North Carolina, United States
Margaret R Pardee Memorial Hospital
🇺🇸
Hendersonville, North Carolina, United States
AdventHealth Hendersonville
🇺🇸
Hendersonville, North Carolina, United States
Novant Health Cancer Institute - Huntersville
🇺🇸
Huntersville, North Carolina, United States
Novant Health Presbyterian Medical Center Huntersville
🇺🇸
Huntersville, North Carolina, United States
Southern Oncology Specialists-Huntersville
🇺🇸
Huntersville, North Carolina, United States
Onslow Memorial Hospital
🇺🇸
Jacksonville, North Carolina, United States
Southeastern Medical Oncology Center-Jacksonville
🇺🇸
Jacksonville, North Carolina, United States
Novant Health Cancer Institute - Kernersville
🇺🇸
Kernersville, North Carolina, United States
Matthews Radiation Oncology Center
🇺🇸
Matthews, North Carolina, United States
Novant Health Cancer Institute - Matthews
🇺🇸
Matthews, North Carolina, United States
Novant Health Cancer Institute - Mooresville
🇺🇸
Mooresville, North Carolina, United States
Novant Health Cancer Institute - Mount Airy
🇺🇸
Mount Airy, North Carolina, United States
Novant Health Cancer Institute - Wilkesboro
🇺🇸
North Wilkesboro, North Carolina, United States
FirstHealth of the Carolinas-Moore Regional Hospital
🇺🇸
Pinehurst, North Carolina, United States
Duke Raleigh Hospital
🇺🇸
Raleigh, North Carolina, United States
Novant Health Cancer Institute - Rowan
🇺🇸
Salisbury, North Carolina, United States
Rowan Regional Medical Center
🇺🇸
Salisbury, North Carolina, United States
Novant Health Cancer Institute - Statesville
🇺🇸
Statesville, North Carolina, United States
Novant Health Cancer Institute - Thomasville
🇺🇸
Thomasville, North Carolina, United States
Marion L Shepard Cancer Center - ECU Health Beaufort Hospital
🇺🇸
Washington, North Carolina, United States
AdventHealth Infusion Center Weaverville
🇺🇸
Weaverville, North Carolina, United States
Novant Health Forsyth Medical Center
🇺🇸
Winston-Salem, North Carolina, United States
Novant Health Oncology Specialists
🇺🇸
Winston-Salem, North Carolina, United States
Winston-Salem Health Care
🇺🇸
Winston-Salem, North Carolina, United States
Wake Forest University Health Sciences
🇺🇸
Winston-Salem, North Carolina, United States
Sanford Bismarck Medical Center
🇺🇸
Bismarck, North Dakota, United States
Essentia Health Cancer Center-South University Clinic
🇺🇸
Fargo, North Dakota, United States
Sanford South University Medical Center
🇺🇸
Fargo, North Dakota, United States
Sanford Broadway Medical Center
🇺🇸
Fargo, North Dakota, United States
Sanford Roger Maris Cancer Center
🇺🇸
Fargo, North Dakota, United States
Essentia Health - Jamestown Clinic
🇺🇸
Jamestown, North Dakota, United States
Trinity Cancer Care Center
🇺🇸
Minot, North Dakota, United States
Aultman Alliance Community Hospital
🇺🇸
Alliance, Ohio, United States
UHHS-Chagrin Highlands Medical Center
🇺🇸
Beachwood, Ohio, United States
Indu and Raj Soin Medical Center
🇺🇸
Beavercreek, Ohio, United States
Strecker Cancer Center-Belpre
🇺🇸
Belpre, Ohio, United States
Saint Elizabeth Boardman Hospital
🇺🇸
Boardman, Ohio, United States
Cleveland Clinic Mercy Hospital
🇺🇸
Canton, Ohio, United States
Mercy Hematology and Oncology Associates Inc
🇺🇸
Canton, Ohio, United States
Aultman Health Foundation
🇺🇸
Canton, Ohio, United States
Dayton Physicians LLC-Miami Valley South
🇺🇸
Centerville, Ohio, United States
Miami Valley Hospital South
🇺🇸
Centerville, Ohio, United States
Geauga Hospital
🇺🇸
Chardon, Ohio, United States
Adena Regional Medical Center
🇺🇸
Chillicothe, Ohio, United States
Oncology Hematology Care Inc-Eden Park
🇺🇸
Cincinnati, Ohio, United States
Oncology Hematology Care Inc-Mercy West
🇺🇸
Cincinnati, Ohio, United States
The Christ Hospital
🇺🇸
Cincinnati, Ohio, United States
Good Samaritan Hospital - Cincinnati
🇺🇸
Cincinnati, Ohio, United States
Cincinnati Children's Hospital Medical Center
🇺🇸
Cincinnati, Ohio, United States
Oncology Hematology Care Inc-Anderson
🇺🇸
Cincinnati, Ohio, United States
Oncology Hematology Care Inc-Kenwood
🇺🇸
Cincinnati, Ohio, United States
Bethesda North Hospital
🇺🇸
Cincinnati, Ohio, United States
Oncology Hematology Care Inc-Blue Ash
🇺🇸
Cincinnati, Ohio, United States
TriHealth Cancer Institute-Westside
🇺🇸
Cincinnati, Ohio, United States
TriHealth Cancer Institute-Anderson
🇺🇸
Cincinnati, Ohio, United States
Case Western Reserve University
🇺🇸
Cleveland, Ohio, United States
MetroHealth Medical Center
🇺🇸
Cleveland, Ohio, United States
Cleveland Clinic Foundation
🇺🇸
Cleveland, Ohio, United States
Ohio State University Comprehensive Cancer Center
🇺🇸
Columbus, Ohio, United States
Mount Carmel East Hospital
🇺🇸
Columbus, Ohio, United States
Columbus Oncology and Hematology Associates Inc
🇺🇸
Columbus, Ohio, United States
Riverside Methodist Hospital
🇺🇸
Columbus, Ohio, United States
Grant Medical Center
🇺🇸
Columbus, Ohio, United States
The Mark H Zangmeister Center
🇺🇸
Columbus, Ohio, United States
Mount Carmel Health Center West
🇺🇸
Columbus, Ohio, United States
Doctors Hospital
🇺🇸
Columbus, Ohio, United States
Good Samaritan Hospital - Dayton
🇺🇸
Dayton, Ohio, United States
Miami Valley Hospital
🇺🇸
Dayton, Ohio, United States
Dayton Physician LLC - Englewood
🇺🇸
Dayton, Ohio, United States
Miami Valley Hospital North
🇺🇸
Dayton, Ohio, United States
Delaware Health Center-Grady Cancer Center
🇺🇸
Delaware, Ohio, United States
Delaware Radiation Oncology
🇺🇸
Delaware, Ohio, United States
Grady Memorial Hospital
🇺🇸
Delaware, Ohio, United States
Columbus Oncology and Hematology Associates
🇺🇸
Dublin, Ohio, United States
Dublin Methodist Hospital
🇺🇸
Dublin, Ohio, United States
Hematology Oncology Center Incorporated
🇺🇸
Elyria, Ohio, United States
Mercy Cancer Center-Elyria
🇺🇸
Elyria, Ohio, United States
Oncology Hematology Care Inc-Healthplex
🇺🇸
Fairfield, Ohio, United States
Armes Family Cancer Center
🇺🇸
Findlay, Ohio, United States
Blanchard Valley Hospital
🇺🇸
Findlay, Ohio, United States
Orion Cancer Care
🇺🇸
Findlay, Ohio, United States
Atrium Medical Center-Middletown Regional Hospital
🇺🇸
Franklin, Ohio, United States
Dayton Physicians LLC-Atrium
🇺🇸
Franklin, Ohio, United States
Dayton Physicians LLC-Wayne
🇺🇸
Greenville, Ohio, United States
Wayne Hospital
🇺🇸
Greenville, Ohio, United States
Mount Carmel Grove City Hospital
🇺🇸
Grove City, Ohio, United States
Greater Dayton Cancer Center
🇺🇸
Kettering, Ohio, United States
First Dayton Cancer Care
🇺🇸
Kettering, Ohio, United States
Kettering Medical Center
🇺🇸
Kettering, Ohio, United States
Fairfield Medical Center
🇺🇸
Lancaster, Ohio, United States
Saint Rita's Medical Center
🇺🇸
Lima, Ohio, United States
Marietta Memorial Hospital
🇺🇸
Marietta, Ohio, United States
OhioHealth Marion General Hospital
🇺🇸
Marion, Ohio, United States
Toledo Clinic Cancer Centers-Maumee
🇺🇸
Maumee, Ohio, United States
Toledo Radiation Oncology at Northwest Ohio Onocolgy Center
🇺🇸
Maumee, Ohio, United States
UH Seidman Cancer Center at Landerbrook Health Center
🇺🇸
Mayfield Heights, Ohio, United States
UH Seidman Cancer Center at Lake Health Mentor Campus
🇺🇸
Mentor, Ohio, United States
UH Seidman Cancer Center at Southwest General Hospital
🇺🇸
Middleburg Heights, Ohio, United States
Dayton Physicians LLC-Signal Point
🇺🇸
Middletown, Ohio, United States
Knox Community Hospital
🇺🇸
Mount Vernon, Ohio, United States
Licking Memorial Hospital
🇺🇸
Newark, Ohio, United States
Newark Radiation Oncology
🇺🇸
Newark, Ohio, United States
Saint Charles Hospital
🇺🇸
Oregon, Ohio, United States
University Hospitals Parma Medical Center
🇺🇸
Parma, Ohio, United States
Mercy Health - Perrysburg Hospital
🇺🇸
Perrysburg, Ohio, United States
Southern Ohio Medical Center
🇺🇸
Portsmouth, Ohio, United States
UH Seidman Cancer Center at Firelands Regional Medical Center
🇺🇸
Sandusky, Ohio, United States
Dayton Physicians LLC-Wilson
🇺🇸
Sidney, Ohio, United States
Springfield Regional Cancer Center
🇺🇸
Springfield, Ohio, United States
Springfield Regional Medical Center
🇺🇸
Springfield, Ohio, United States
Trinity's Tony Teramana Cancer Center
🇺🇸
Steubenville, Ohio, United States
ProMedica Flower Hospital
🇺🇸
Sylvania, Ohio, United States
ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital
🇺🇸
Toledo, Ohio, United States
Mercy Health - Saint Vincent Hospital
🇺🇸
Toledo, Ohio, United States
University of Toledo
🇺🇸
Toledo, Ohio, United States
Mercy Health - Saint Anne Hospital
🇺🇸
Toledo, Ohio, United States
Toledo Clinic Cancer Centers-Toledo
🇺🇸
Toledo, Ohio, United States
Dayton Physicians LLC - Troy
🇺🇸
Troy, Ohio, United States
Upper Valley Medical Center
🇺🇸
Troy, Ohio, United States
University Hospitals Sharon Health Center
🇺🇸
Wadsworth, Ohio, United States
Saint Joseph Warren Hospital
🇺🇸
Warren, Ohio, United States
Saint Ann's Hospital
🇺🇸
Westerville, Ohio, United States
UH Seidman Cancer Center at Saint John Medical Center
🇺🇸
Westlake, Ohio, United States
UHHS-Westlake Medical Center
🇺🇸
Westlake, Ohio, United States
Saint Elizabeth Youngstown Hospital
🇺🇸
Youngstown, Ohio, United States
Genesis Healthcare System Cancer Care Center
🇺🇸
Zanesville, Ohio, United States
Cancer Centers of Southwest Oklahoma Research
🇺🇸
Lawton, Oklahoma, United States
University of Oklahoma Health Sciences Center
🇺🇸
Oklahoma City, Oklahoma, United States
Integris Southwest Medical Center
🇺🇸
Oklahoma City, Oklahoma, United States
Mercy Hospital Oklahoma City
🇺🇸
Oklahoma City, Oklahoma, United States
Integris Cancer Institute of Oklahoma
🇺🇸
Oklahoma City, Oklahoma, United States
Cancer Treatment Centers of America
🇺🇸
Tulsa, Oklahoma, United States
Oklahoma Cancer Specialists and Research Institute-Tulsa
🇺🇸
Tulsa, Oklahoma, United States
Saint Alphonsus Cancer Care Center-Baker City
🇺🇸
Baker City, Oregon, United States
Saint Charles Health System
🇺🇸
Bend, Oregon, United States
Clackamas Radiation Oncology Center
🇺🇸
Clackamas, Oregon, United States
Providence Cancer Institute Clackamas Clinic
🇺🇸
Clackamas, Oregon, United States
Bay Area Hospital
🇺🇸
Coos Bay, Oregon, United States
Good Samaritan Hospital
🇺🇸
Corvallis, Oregon, United States
Legacy Mount Hood Medical Center
🇺🇸
Gresham, Oregon, United States
Providence Newberg Medical Center
🇺🇸
Newberg, Oregon, United States
Saint Alphonsus Cancer Care Center-Ontario
🇺🇸
Ontario, Oregon, United States
Providence Willamette Falls Medical Center
🇺🇸
Oregon City, Oregon, United States
Legacy Good Samaritan Hospital and Medical Center
🇺🇸
Portland, Oregon, United States
Providence Portland Medical Center
🇺🇸
Portland, Oregon, United States
Providence Saint Vincent Medical Center
🇺🇸
Portland, Oregon, United States
Kaiser Permanente Northwest
🇺🇸
Portland, Oregon, United States
Saint Charles Health System-Redmond
🇺🇸
Redmond, Oregon, United States
Legacy Meridian Park Hospital
🇺🇸
Tualatin, Oregon, United States
Jefferson Abington Hospital
🇺🇸
Abington, Pennsylvania, United States
Lehigh Valley Hospital-Cedar Crest
🇺🇸
Allentown, Pennsylvania, United States
UPMC Altoona
🇺🇸
Altoona, Pennsylvania, United States
UPMC-Heritage Valley Health System Beaver
🇺🇸
Beaver, Pennsylvania, United States
Lehigh Valley Hospital - Muhlenberg
🇺🇸
Bethlehem, Pennsylvania, United States
Bryn Mawr Hospital
🇺🇸
Bryn Mawr, Pennsylvania, United States
UPMC Hillman Cancer Center at Butler Health System
🇺🇸
Butler, Pennsylvania, United States
UPMC Camp Hill
🇺🇸
Camp Hill, Pennsylvania, United States
Carlisle Regional Cancer Center
🇺🇸
Carlisle, Pennsylvania, United States
Christiana Care Health System-Concord Health Center
🇺🇸
Chadds Ford, Pennsylvania, United States
Chambersburg Hospital
🇺🇸
Chambersburg, Pennsylvania, United States
Main Line Health Center-Collegeville
🇺🇸
Collegeville, Pennsylvania, United States
UPMC Hillman Cancer Center - Passavant - Cranberry
🇺🇸
Cranberry Township, Pennsylvania, United States
Geisinger Medical Center
🇺🇸
Danville, Pennsylvania, United States
Doylestown Hospital
🇺🇸
Doylestown, Pennsylvania, United States
Pocono Medical Center
🇺🇸
East Stroudsburg, Pennsylvania, United States
Easton Hospital
🇺🇸
Easton, Pennsylvania, United States
Ephrata Cancer Center
🇺🇸
Ephrata, Pennsylvania, United States
Ephrata Community Hospital
🇺🇸
Ephrata, Pennsylvania, United States
UPMC Hillman Cancer Center Erie
🇺🇸
Erie, Pennsylvania, United States
UPMC Hamot
🇺🇸
Erie, Pennsylvania, United States
Main Line Health Center-Exton
🇺🇸
Exton, Pennsylvania, United States
UPMC Cancer Center at UPMC Horizon
🇺🇸
Farrell, Pennsylvania, United States
Adams Cancer Center
🇺🇸
Gettysburg, Pennsylvania, United States
UPMC Cancer Centers - Arnold Palmer Pavilion
🇺🇸
Greensburg, Pennsylvania, United States
Oncology Hematology Associates
🇺🇸
Greenville, Pennsylvania, United States
WellSpan Medical Oncology and Hematology
🇺🇸
Hanover, Pennsylvania, United States
UPMC Pinnacle Harrisburg
🇺🇸
Harrisburg, Pennsylvania, United States
UPMC Pinnacle Cancer Center/Community Osteopathic Campus
🇺🇸
Harrisburg, Pennsylvania, United States
Geisinger Medical Center-Cancer Center Hazleton
🇺🇸
Hazleton, Pennsylvania, United States
Lehigh Valley Hospital-Hazleton
🇺🇸
Hazleton, Pennsylvania, United States
Penn State Milton S Hershey Medical Center
🇺🇸
Hershey, Pennsylvania, United States
IRMC Cancer Center
🇺🇸
Indiana, Pennsylvania, United States
UPMC-Johnstown/John P. Murtha Regional Cancer Center
🇺🇸
Johnstown, Pennsylvania, United States
Armstrong Center for Medicine and Health
🇺🇸
Kittanning, Pennsylvania, United States
Lancaster General Ann B Barshinger Cancer Institute
🇺🇸
Lancaster, Pennsylvania, United States
Lancaster General Hospital
🇺🇸
Lancaster, Pennsylvania, United States
Sechler Family Cancer Center
🇺🇸
Lebanon, Pennsylvania, United States
Geisinger Medical Oncology-Lewisburg
🇺🇸
Lewisburg, Pennsylvania, United States
Lewistown Hospital
🇺🇸
Lewistown, Pennsylvania, United States
UPMC Cancer Center at UPMC McKeesport
🇺🇸
McKeesport, Pennsylvania, United States
Redeemer Health
🇺🇸
Meadowbrook, Pennsylvania, United States
UPMC Hillman Cancer Center at Rocco And Nancy Ortenzio Cancer Pavilion
🇺🇸
Mechanicsburg, Pennsylvania, United States
Riddle Memorial Hospital
🇺🇸
Media, Pennsylvania, United States
Forbes Hospital
🇺🇸
Monroeville, Pennsylvania, United States
UPMC Hillman Cancer Center - Monroeville
🇺🇸
Monroeville, Pennsylvania, United States
UPMC Hillman Cancer Center in Coraopolis
🇺🇸
Moon, Pennsylvania, United States
UPMC Hillman Cancer Center - Part of Frick Hospital
🇺🇸
Mount Pleasant, Pennsylvania, United States
Arnold Palmer Cancer Center Medical Oncology Norwin
🇺🇸
N. Huntingdon, Pennsylvania, United States
Allegheny Valley Hospital
🇺🇸
Natrona Heights, Pennsylvania, United States
UPMC Cancer Center-Natrona Heights
🇺🇸
Natrona Heights, Pennsylvania, United States
UPMC Hillman Cancer Center - New Castle
🇺🇸
New Castle, Pennsylvania, United States
Suburban Community Hospital and Cancer Center
🇺🇸
Norristown, Pennsylvania, United States
Paoli Memorial Hospital
🇺🇸
Paoli, Pennsylvania, United States
Drexel University School of Medicine
🇺🇸
Philadelphia, Pennsylvania, United States
Thomas Jefferson University Hospital
🇺🇸
Philadelphia, Pennsylvania, United States
Fox Chase Cancer Center
🇺🇸
Philadelphia, Pennsylvania, United States
Jefferson Torresdale Hospital
🇺🇸
Philadelphia, Pennsylvania, United States
Eastern Regional Medical Center
🇺🇸
Philadelphia, Pennsylvania, United States
Nazareth Hospital
🇺🇸
Philadelphia, Pennsylvania, United States
Phoenixville Hospital
🇺🇸
Phoenixville, Pennsylvania, United States
Allegheny General Hospital
🇺🇸
Pittsburgh, Pennsylvania, United States
UPMC-Magee Womens Hospital
🇺🇸
Pittsburgh, Pennsylvania, United States
Oncology Hematology Association
🇺🇸
Pittsburgh, Pennsylvania, United States
UPMC-Saint Margaret
🇺🇸
Pittsburgh, Pennsylvania, United States
UPMC-Mercy Hospital
🇺🇸
Pittsburgh, Pennsylvania, United States
West Penn Hospital
🇺🇸
Pittsburgh, Pennsylvania, United States
University of Pittsburgh Cancer Institute (UPCI)
🇺🇸
Pittsburgh, Pennsylvania, United States
UPMC-Passavant Hospital
🇺🇸
Pittsburgh, Pennsylvania, United States
UPMC-Saint Clair Hospital Cancer Center
🇺🇸
Pittsburgh, Pennsylvania, United States
Geisinger Cancer Services-Pottsville
🇺🇸
Pottsville, Pennsylvania, United States
Penn State Health Saint Joseph Medical Center
🇺🇸
Reading, Pennsylvania, United States
Guthrie Medical Group PC-Robert Packer Hospital
🇺🇸
Sayre, Pennsylvania, United States
Hematology and Oncology Associates of North East Pennsylvania
🇺🇸
Scranton, Pennsylvania, United States
Geisinger Medical Oncology-Selinsgrove
🇺🇸
Selinsgrove, Pennsylvania, United States
UPMC Cancer Center at UPMC Northwest
🇺🇸
Seneca, Pennsylvania, United States
Geisinger Medical Group
🇺🇸
State College, Pennsylvania, United States
Mount Nittany Medical Center
🇺🇸
State College, Pennsylvania, United States
UPMC Cancer Center-Uniontown
🇺🇸
Uniontown, Pennsylvania, United States
UPMC Cancer Center-Washington
🇺🇸
Washington, Pennsylvania, United States
Chester County Hospital
🇺🇸
West Chester, Pennsylvania, United States
UPMC West Mifflin-Cancer Center Jefferson
🇺🇸
West Mifflin, Pennsylvania, United States
Reading Hospital
🇺🇸
West Reading, Pennsylvania, United States
Geisinger Wyoming Valley/Henry Cancer Center
🇺🇸
Wilkes-Barre, Pennsylvania, United States
UPMC Susquehanna
🇺🇸
Williamsport, Pennsylvania, United States
Divine Providence Hospital
🇺🇸
Williamsport, Pennsylvania, United States
Asplundh Cancer Pavilion
🇺🇸
Willow Grove, Pennsylvania, United States
Lankenau Medical Center
🇺🇸
Wynnewood, Pennsylvania, United States
Cancer Care Associates of York
🇺🇸
York, Pennsylvania, United States
WellSpan Health-York Cancer Center
🇺🇸
York, Pennsylvania, United States
WellSpan Health-York Hospital
🇺🇸
York, Pennsylvania, United States
UPMC Memorial
🇺🇸
York, Pennsylvania, United States
Newport Hospital
🇺🇸
Newport, Rhode Island, United States
Rhode Island Hospital
🇺🇸
Providence, Rhode Island, United States
Women and Infants Hospital
🇺🇸
Providence, Rhode Island, United States
Miriam Hospital
🇺🇸
Providence, Rhode Island, United States
Smilow Cancer Hospital Care Center - Westerly
🇺🇸
Westerly, Rhode Island, United States
AnMed Health Cancer Center
🇺🇸
Anderson, South Carolina, United States
Beaufort Memorial Hospital
🇺🇸
Beaufort, South Carolina, United States
Prisma Health Cancer Institute - Spartanburg
🇺🇸
Boiling Springs, South Carolina, United States
Roper Hospital
🇺🇸
Charleston, South Carolina, United States
Charleston Oncology - Roper
🇺🇸
Charleston, South Carolina, United States
Lowcountry Hematology Oncology PA-North Charleston
🇺🇸
Charleston, South Carolina, United States
Bon Secours Saint Francis Hospital
🇺🇸
Charleston, South Carolina, United States
Charleston Oncology - Saint Francis
🇺🇸
Charleston, South Carolina, United States
Lowcountry Hematology Oncology PA-West Ashley
🇺🇸
Charleston, South Carolina, United States
Medical University of South Carolina
🇺🇸
Charleston, South Carolina, United States
Prisma Health Cancer Institute - Easley
🇺🇸
Easley, South Carolina, United States
McLeod Regional Medical Center
🇺🇸
Florence, South Carolina, United States
Gibbs Cancer Center-Gaffney
🇺🇸
Gaffney, South Carolina, United States
Tidelands Georgetown Memorial Hospital
🇺🇸
Georgetown, South Carolina, United States
Greenville Health System Cancer Institute-Andrews
🇺🇸
Greenville, South Carolina, United States
Prisma Health Cancer Institute - Butternut
🇺🇸
Greenville, South Carolina, United States
Prisma Health Cancer Institute - Faris
🇺🇸
Greenville, South Carolina, United States
Prisma Health Greenville Memorial Hospital
🇺🇸
Greenville, South Carolina, United States
Prisma Health Cancer Institute - Eastside
🇺🇸
Greenville, South Carolina, United States
Self Regional Healthcare
🇺🇸
Greenwood, South Carolina, United States
Prisma Health Cancer Institute - Greer
🇺🇸
Greer, South Carolina, United States
Gibbs Cancer Center-Pelham
🇺🇸
Greer, South Carolina, United States
South Carolina Cancer Specialists PC
🇺🇸
Hilton Head Island, South Carolina, United States
The Radiation Oncology Center-Hilton Head/Bluffton
🇺🇸
Hilton Head Island, South Carolina, United States
Lowcountry Hematology Oncology PA-Mount Pleasant
🇺🇸
Mount Pleasant, South Carolina, United States
Prisma Health Cancer Institute - Seneca
🇺🇸
Seneca, South Carolina, United States
North Grove Medical Park
🇺🇸
Spartanburg, South Carolina, United States
Spartanburg Medical Center
🇺🇸
Spartanburg, South Carolina, United States
Spartanburg Medical Center - Mary Black Campus
🇺🇸
Spartanburg, South Carolina, United States
MGC Hematology Oncology-Union
🇺🇸
Union, South Carolina, United States
Avera Cancer Institute-Aberdeen
🇺🇸
Aberdeen, South Dakota, United States
Rapid City Regional Hospital
🇺🇸
Rapid City, South Dakota, United States
Sanford Cancer Center Oncology Clinic
🇺🇸
Sioux Falls, South Dakota, United States
Avera Cancer Institute
🇺🇸
Sioux Falls, South Dakota, United States
Sanford USD Medical Center - Sioux Falls
🇺🇸
Sioux Falls, South Dakota, United States
Memorial Hospital
🇺🇸
Chattanooga, Tennessee, United States
Integrity Oncology PLLC-Collierville
🇺🇸
Collierville, Tennessee, United States
Cookeville Regional Medical Center
🇺🇸
Cookeville, Tennessee, United States
Vanderbilt-Ingram Cancer Center Cool Springs
🇺🇸
Franklin, Tennessee, United States
Pulmonary Medicine Center of Chattanooga-Hixson
🇺🇸
Hixson, Tennessee, United States
Tennessee Cancer Specialists-Dowell Springs
🇺🇸
Knoxville, Tennessee, United States
Thompson Cancer Survival Center
🇺🇸
Knoxville, Tennessee, United States
Thompson Cancer Survival Center - West
🇺🇸
Knoxville, Tennessee, United States
Thompson Oncology Group-Maryville
🇺🇸
Maryville, Tennessee, United States
Baptist Memorial Hospital and Cancer Center-Memphis
🇺🇸
Memphis, Tennessee, United States
Family Cancer Center-Memphis
🇺🇸
Memphis, Tennessee, United States
Vanderbilt Breast Center at One Hundred Oaks
🇺🇸
Nashville, Tennessee, United States
Meharry Medical College
🇺🇸
Nashville, Tennessee, United States
Vanderbilt University/Ingram Cancer Center
🇺🇸
Nashville, Tennessee, United States
Thompson Oncology Group-Oak Ridge
🇺🇸
Oak Ridge, Tennessee, United States
Memorial GYN Plus
🇺🇸
Ooltewah, Tennessee, United States
Dell Seton Medical Center at The University of Texas
🇺🇸
Austin, Texas, United States
Saint Joseph Regional Cancer Center
🇺🇸
Bryan, Texas, United States
MD Anderson in The Woodlands
🇺🇸
Conroe, Texas, United States
Parkland Memorial Hospital
🇺🇸
Dallas, Texas, United States
Baylor University Medical Center
🇺🇸
Dallas, Texas, United States
UT Southwestern/Simmons Cancer Center-Dallas
🇺🇸
Dallas, Texas, United States
UT Southwestern/Simmons Cancer Center-Fort Worth
🇺🇸
Fort Worth, Texas, United States
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center
🇺🇸
Houston, Texas, United States
Houston Methodist Hospital
🇺🇸
Houston, Texas, United States
M D Anderson Cancer Center
🇺🇸
Houston, Texas, United States
Memorial Hermann Texas Medical Center
🇺🇸
Houston, Texas, United States
MD Anderson West Houston
🇺🇸
Houston, Texas, United States
Memorial Hermann Northeast Hospital
🇺🇸
Humble, Texas, United States
MD Anderson League City
🇺🇸
League City, Texas, United States
Covenant Medical Center-Lakeside
🇺🇸
Lubbock, Texas, United States
UT Southwestern Clinical Center at Richardson/Plano
🇺🇸
Richardson, Texas, United States
Cancer Therapy and Research Center at The UT Health Science Center at San Antonio
🇺🇸
San Antonio, Texas, United States
Methodist Children's Hospital of South Texas
🇺🇸
San Antonio, Texas, United States
University Hospital
🇺🇸
San Antonio, Texas, United States
University of Texas Health Science Center at San Antonio
🇺🇸
San Antonio, Texas, United States
MD Anderson in Sugar Land
🇺🇸
Sugar Land, Texas, United States
Memorial Hermann The Woodlands Hospital
🇺🇸
The Woodlands, Texas, United States
American Fork Hospital / Huntsman Intermountain Cancer Center
🇺🇸
American Fork, Utah, United States
Sandra L Maxwell Cancer Center
🇺🇸
Cedar City, Utah, United States
Farmington Health Center
🇺🇸
Farmington, Utah, United States
Logan Regional Hospital
🇺🇸
Logan, Utah, United States
Intermountain Medical Center
🇺🇸
Murray, Utah, United States
McKay-Dee Hospital Center
🇺🇸
Ogden, Utah, United States
Utah Valley Regional Medical Center
🇺🇸
Provo, Utah, United States
Riverton Hospital
🇺🇸
Riverton, Utah, United States
Saint George Regional Medical Center
🇺🇸
Saint George, Utah, United States
University of Utah Sugarhouse Health Center
🇺🇸
Salt Lake City, Utah, United States
Utah Cancer Specialists-Salt Lake City
🇺🇸
Salt Lake City, Utah, United States
Huntsman Cancer Institute/University of Utah
🇺🇸
Salt Lake City, Utah, United States
LDS Hospital
🇺🇸
Salt Lake City, Utah, United States
South Jordan Health Center
🇺🇸
South Jordan, Utah, United States
Central Vermont Medical Center/National Life Cancer Treatment
🇺🇸
Berlin, Vermont, United States
University of Vermont Medical Center
🇺🇸
Burlington, Vermont, United States
University of Vermont and State Agricultural College
🇺🇸
Burlington, Vermont, United States
Dartmouth Cancer Center - North
🇺🇸
Saint Johnsbury, Vermont, United States
Danville Regional Medical Center
🇺🇸
Danville, Virginia, United States
Inova Schar Cancer Institute
🇺🇸
Fairfax, Virginia, United States
Inova Fair Oaks Hospital
🇺🇸
Fairfax, Virginia, United States
Inova Fairfax Hospital
🇺🇸
Falls Church, Virginia, United States
Augusta Health Center for Cancer and Blood Disorders
🇺🇸
Fishersville, Virginia, United States
Hematology Oncology Associates of Fredericksburg Inc
🇺🇸
Fredericksburg, Virginia, United States
Centra Alan B Pearson Regional Cancer Center
🇺🇸
Lynchburg, Virginia, United States
Sovah Health Martinsville
🇺🇸
Martinsville, Virginia, United States
Bon Secours Memorial Regional Medical Center
🇺🇸
Mechanicsville, Virginia, United States
Bon Secours Westchester Emergency Center
🇺🇸
Midlothian, Virginia, United States
Bon Secours Saint Francis Medical Center
🇺🇸
Midlothian, Virginia, United States
Children's Hospital of The King's Daughters
🇺🇸
Norfolk, Virginia, United States
Bon Secours Saint Mary's Hospital
🇺🇸
Richmond, Virginia, United States
Virginia Cancer Institute
🇺🇸
Richmond, Virginia, United States
Bon Secours Cancer Institute at Reynolds Crossing
🇺🇸
Richmond, Virginia, United States
VCU Massey Cancer Center at Stony Point
🇺🇸
Richmond, Virginia, United States
Virginia Commonwealth University/Massey Cancer Center
🇺🇸
Richmond, Virginia, United States
Providence Regional Cancer System-Aberdeen
🇺🇸
Aberdeen, Washington, United States
Cancer Care Center at Island Hospital
🇺🇸
Anacortes, Washington, United States
MultiCare Auburn Medical Center
🇺🇸
Auburn, Washington, United States
Virginia Mason Bainbridge Island Medical Center
🇺🇸
Bainbridge Island, Washington, United States
Overlake Medical Center
🇺🇸
Bellevue, Washington, United States
Swedish Cancer Institute-Eastside Oncology Hematology
🇺🇸
Bellevue, Washington, United States
PeaceHealth Saint Joseph Medical Center
🇺🇸
Bellingham, Washington, United States
Harrison HealthPartners Hematology and Oncology-Bremerton
🇺🇸
Bremerton, Washington, United States
Highline Medical Center-Main Campus
🇺🇸
Burien, Washington, United States
Providence Regional Cancer System-Centralia
🇺🇸
Centralia, Washington, United States
Swedish Cancer Institute-Edmonds
🇺🇸
Edmonds, Washington, United States
Saint Elizabeth Hospital
🇺🇸
Enumclaw, Washington, United States
Providence Regional Cancer Partnership
🇺🇸
Everett, Washington, United States
Virginia Mason Federal Way Medical Center
🇺🇸
Federal Way, Washington, United States
Tacoma/Valley Radiation Oncology Centers-Gig Harbor
🇺🇸
Gig Harbor, Washington, United States
MultiCare Gig Harbor Medical Park
🇺🇸
Gig Harbor, Washington, United States
Swedish Cancer Institute-Issaquah
🇺🇸
Issaquah, Washington, United States
Kadlec Clinic Hematology and Oncology
🇺🇸
Kennewick, Washington, United States
Northwest Cancer Clinic
🇺🇸
Kennewick, Washington, United States
Providence Regional Cancer System-Lacey
🇺🇸
Lacey, Washington, United States
Saint Clare Hospital
🇺🇸
Lakewood, Washington, United States
PeaceHealth Saint John Medical Center
🇺🇸
Longview, Washington, United States
Virginia Mason Lynnwood Medical Center
🇺🇸
Lynnwood, Washington, United States
Skagit Regional Health Cancer Care Center
🇺🇸
Mount Vernon, Washington, United States
Skagit Valley Hospital
🇺🇸
Mount Vernon, Washington, United States
Jefferson Healthcare
🇺🇸
Port Townsend, Washington, United States
Harrison HealthPartners Hematology and Oncology-Poulsbo
🇺🇸
Poulsbo, Washington, United States
Peninsula Cancer Center
🇺🇸
Poulsbo, Washington, United States
MultiCare Good Samaritan Hospital
🇺🇸
Puyallup, Washington, United States
Tacoma/Valley Radiation Oncology Centers-Puyallup
🇺🇸
Puyallup, Washington, United States
Valley Medical Center
🇺🇸
Renton, Washington, United States
Virginia Mason Medical Center
🇺🇸
Seattle, Washington, United States
Minor and James Medical PLLC
🇺🇸
Seattle, Washington, United States
Pacific Gynecology Specialists
🇺🇸
Seattle, Washington, United States
Swedish Medical Center-Ballard Campus
🇺🇸
Seattle, Washington, United States
FHCC South Lake Union
🇺🇸
Seattle, Washington, United States
Fred Hutchinson Cancer Center
🇺🇸
Seattle, Washington, United States
Kaiser Permanente Washington
🇺🇸
Seattle, Washington, United States
Swedish Medical Center-Cherry Hill
🇺🇸
Seattle, Washington, United States
Swedish Medical Center-First Hill
🇺🇸
Seattle, Washington, United States
University of Washington Medical Center - Montlake
🇺🇸
Seattle, Washington, United States
PeaceHealth United General Medical Center
🇺🇸
Sedro-Woolley, Washington, United States
Providence Regional Cancer System-Shelton
🇺🇸
Shelton, Washington, United States
Saint Michael Cancer Center
🇺🇸
Silverdale, Washington, United States
MultiCare Deaconess Cancer and Blood Specialty Center - Valley
🇺🇸
Spokane Valley, Washington, United States
MultiCare Deaconess Cancer and Blood Specialty Center - Downtown
🇺🇸
Spokane, Washington, United States
Providence Sacred Heart Medical Center and Children's Hospital
🇺🇸
Spokane, Washington, United States
Spokane Valley Cancer Center-Mayfair
🇺🇸
Spokane, Washington, United States
Spokane Valley Cancer Center-Mission
🇺🇸
Spokane, Washington, United States
Evergreen Hematology and Oncology PS
🇺🇸
Spokane, Washington, United States
MultiCare Deaconess Cancer and Blood Specialty Center - North
🇺🇸
Spokane, Washington, United States
Tacoma/Valley Radiation Oncology Centers-Jackson Hall
🇺🇸
Tacoma, Washington, United States
Franciscan Research Center-Northwest Medical Plaza
🇺🇸
Tacoma, Washington, United States
Mary Bridge Children's Hospital and Health Center
🇺🇸
Tacoma, Washington, United States
MultiCare Tacoma General Hospital
🇺🇸
Tacoma, Washington, United States
Northwest Medical Specialties PLLC
🇺🇸
Tacoma, Washington, United States
Tacoma/Valley Radiation Oncology Centers-Saint Joe's
🇺🇸
Tacoma, Washington, United States
PeaceHealth Southwest Medical Center
🇺🇸
Vancouver, Washington, United States
Legacy Cancer Institute Medical Oncology and Day Treatment
🇺🇸
Vancouver, Washington, United States
Legacy Salmon Creek Hospital
🇺🇸
Vancouver, Washington, United States
Providence Saint Mary Regional Cancer Center
🇺🇸
Walla Walla, Washington, United States
Wenatchee Valley Hospital and Clinics
🇺🇸
Wenatchee, Washington, United States
North Star Lodge Cancer Center at Yakima Valley Memorial Hospital
🇺🇸
Yakima, Washington, United States
Providence Regional Cancer System-Yelm
🇺🇸
Yelm, Washington, United States
United Hospital Center
🇺🇸
Bridgeport, West Virginia, United States
West Virginia University Charleston Division
🇺🇸
Charleston, West Virginia, United States
Edwards Comprehensive Cancer Center
🇺🇸
Huntington, West Virginia, United States
WVUH-Berkely Medical Center
🇺🇸
Martinsburg, West Virginia, United States
Monongalia Hospital
🇺🇸
Morgantown, West Virginia, United States
West Virginia University Healthcare
🇺🇸
Morgantown, West Virginia, United States
Camden Clark Medical Center
🇺🇸
Parkersburg, West Virginia, United States
Wheeling Hospital/Schiffler Cancer Center
🇺🇸
Wheeling, West Virginia, United States
Langlade Hospital and Cancer Center
🇺🇸
Antigo, Wisconsin, United States
Ascension Saint Elizabeth Hospital
🇺🇸
Appleton, Wisconsin, United States
Duluth Clinic Ashland
🇺🇸
Ashland, Wisconsin, United States
Northwest Wisconsin Cancer Center
🇺🇸
Ashland, Wisconsin, United States
Ascension Southeast Wisconsin Hospital - Elmbrook Campus
🇺🇸
Brookfield, Wisconsin, United States
Aurora Cancer Care-Southern Lakes VLCC
🇺🇸
Burlington, Wisconsin, United States
Ascension Calumet Hospital
🇺🇸
Chilton, Wisconsin, United States
Marshfield Clinic-Chippewa Center
🇺🇸
Chippewa Falls, Wisconsin, United States
HSHS Sacred Heart Hospital
🇺🇸
Eau Claire, Wisconsin, United States
Aurora Saint Luke's South Shore
🇺🇸
Cudahy, Wisconsin, United States
Marshfield Clinic Cancer Center at Sacred Heart
🇺🇸
Eau Claire, Wisconsin, United States
Marshfield Medical Center-EC Cancer Center
🇺🇸
Eau Claire, Wisconsin, United States
Aurora Health Center-Fond du Lac
🇺🇸
Fond Du Lac, Wisconsin, United States
Ascension Saint Francis - Reiman Cancer Center
🇺🇸
Franklin, Wisconsin, United States
Ascension Southeast Wisconsin Hospital - Franklin
🇺🇸
Franklin, Wisconsin, United States
Aurora Health Care Germantown Health Center
🇺🇸
Germantown, Wisconsin, United States
Aurora Cancer Care-Grafton
🇺🇸
Grafton, Wisconsin, United States
Green Bay Oncology at Saint Vincent Hospital
🇺🇸
Green Bay, Wisconsin, United States
Saint Vincent Hospital Cancer Center Green Bay
🇺🇸
Green Bay, Wisconsin, United States
Saint Vincent Hospital Cancer Center at Saint Mary's
🇺🇸
Green Bay, Wisconsin, United States
Aurora BayCare Medical Center
🇺🇸
Green Bay, Wisconsin, United States
Mercyhealth Hospital and Cancer Center - Janesville
🇺🇸
Janesville, Wisconsin, United States
Aurora Cancer Care-Kenosha South
🇺🇸
Kenosha, Wisconsin, United States
Gundersen Lutheran Medical Center
🇺🇸
La Crosse, Wisconsin, United States
Marshfield Medical Center - Ladysmith
🇺🇸
Ladysmith, Wisconsin, United States
University of Wisconsin Carbone Cancer Center - University Hospital
🇺🇸
Madison, Wisconsin, United States
Holy Family Memorial Hospital
🇺🇸
Manitowoc, Wisconsin, United States
Aurora Bay Area Medical Group-Marinette
🇺🇸
Marinette, Wisconsin, United States
Saint Vincent Hospital Cancer Center at Marinette
🇺🇸
Marinette, Wisconsin, United States
Marshfield Medical Center-Marshfield
🇺🇸
Marshfield, Wisconsin, United States
Marshfield Medical Center
🇺🇸
Marshfield, Wisconsin, United States
Aspirus Medford Hospital
🇺🇸
Medford, Wisconsin, United States
Ascension Columbia Saint Mary's Hospital Ozaukee
🇺🇸
Mequon, Wisconsin, United States
Aurora Cancer Care-Milwaukee
🇺🇸
Milwaukee, Wisconsin, United States
Ascension Southeast Wisconsin Hospital - Saint Joseph Campus
🇺🇸
Milwaukee, Wisconsin, United States
Ascension Columbia Saint Mary's Hospital - Milwaukee
🇺🇸
Milwaukee, Wisconsin, United States
Ascension Saint Francis Hospital
🇺🇸
Milwaukee, Wisconsin, United States
Aurora Saint Luke's Medical Center
🇺🇸
Milwaukee, Wisconsin, United States
Medical College of Wisconsin
🇺🇸
Milwaukee, Wisconsin, United States
Aurora Sinai Medical Center
🇺🇸
Milwaukee, Wisconsin, United States
Marshfield Medical Center - Minocqua
🇺🇸
Minocqua, Wisconsin, United States
ProHealth D N Greenwald Center
🇺🇸
Mukwonago, Wisconsin, United States
Cancer Center of Western Wisconsin
🇺🇸
New Richmond, Wisconsin, United States
ProHealth Oconomowoc Memorial Hospital
🇺🇸
Oconomowoc, Wisconsin, United States
Saint Vincent Hospital Cancer Center at Oconto Falls
🇺🇸
Oconto Falls, Wisconsin, United States
Ascension Mercy Hospital
🇺🇸
Oshkosh, Wisconsin, United States
Vince Lombardi Cancer Clinic - Oshkosh
🇺🇸
Oshkosh, Wisconsin, United States
Ascension All Saints Hospital
🇺🇸
Racine, Wisconsin, United States
Aurora Cancer Care-Racine
🇺🇸
Racine, Wisconsin, United States
Aspirus Cancer Care - James Beck Cancer Center
🇺🇸
Rhinelander, Wisconsin, United States
Saint Mary's Hospital
🇺🇸
Rhinelander, Wisconsin, United States
Lakeview Medical Center-Marshfield Clinic
🇺🇸
Rice Lake, Wisconsin, United States
Marshfield Medical Center-Rice Lake
🇺🇸
Rice Lake, Wisconsin, United States
HSHS Saint Nicholas Hospital
🇺🇸
Sheboygan, Wisconsin, United States
Vince Lombardi Cancer Clinic-Sheboygan
🇺🇸
Sheboygan, Wisconsin, United States
Aspirus Cancer Care - Stevens Point
🇺🇸
Stevens Point, Wisconsin, United States
Marshfield Medical Center-River Region at Stevens Point
🇺🇸
Stevens Point, Wisconsin, United States
Saint Vincent Hospital Cancer Center at Sturgeon Bay
🇺🇸
Sturgeon Bay, Wisconsin, United States
Aurora Medical Center in Summit
🇺🇸
Summit, Wisconsin, United States
Vince Lombardi Cancer Clinic-Two Rivers
🇺🇸
Two Rivers, Wisconsin, United States
Aurora Cancer Care-Waukesha
🇺🇸
Waukesha, Wisconsin, United States
ProHealth Waukesha Memorial Hospital
🇺🇸
Waukesha, Wisconsin, United States
UW Cancer Center at ProHealth Care
🇺🇸
Waukesha, Wisconsin, United States
Aspirus Regional Cancer Center
🇺🇸
Wausau, Wisconsin, United States
Marshfield Clinic-Wausau Center
🇺🇸
Wausau, Wisconsin, United States
Ascension Medical Group Southeast Wisconsin - Mayfair Road
🇺🇸
Wauwatosa, Wisconsin, United States
Aurora Cancer Care-Milwaukee West
🇺🇸
Wauwatosa, Wisconsin, United States
Aurora West Allis Medical Center
🇺🇸
West Allis, Wisconsin, United States
Diagnostic and Treatment Center
🇺🇸
Weston, Wisconsin, United States
Marshfield Medical Center - Weston
🇺🇸
Weston, Wisconsin, United States
Aspirus Cancer Care - Wisconsin Rapids
🇺🇸
Wisconsin Rapids, Wisconsin, United States
Marshfield Clinic - Wisconsin Rapids Center
🇺🇸
Wisconsin Rapids, Wisconsin, United States
Cheyenne Regional Medical Center-West
🇺🇸
Cheyenne, Wyoming, United States
Big Horn Basin Cancer Center
🇺🇸
Cody, Wyoming, United States
Billings Clinic-Cody
🇺🇸
Cody, Wyoming, United States
Welch Cancer Center
🇺🇸
Sheridan, Wyoming, United States
FHP Health Center-Guam
🇬🇺
Tamuning, Guam
Cancer Center-Metro Medical Center Bayamon
🇵🇷
Bayamon, Puerto Rico
Doctors Cancer Center
🇵🇷
Manati, Puerto Rico
San Juan Community Oncology Group
🇵🇷
San Juan, Puerto Rico
San Juan City Hospital
🇵🇷
San Juan, Puerto Rico

Related News

pmc.ncbi.nlm.nih.gov

9 years ago

Precision Oncology Medicine: The Clinical Relevance ...

Precision oncology leverages patient-specific biomarkers to optimize cancer treatment, utilizing genomic diagnostics and targeted therapeutics. Key advancements include companion diagnostics for drug-target pairs, multigene expression assays, and Next-Generation Sequencing for actionable mutations. Clinical trials like NCI-MATCH explore novel diagnostics and therapies, aiming to enhance precision medicine's clinical utility and future development.

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Recruitment & Eligibility

Study & Design

Trial Locations

Related News

Precision Oncology Medicine: The Clinical Relevance ...

Instant Trial Alerts

Instant Trial Alerts